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ABSTRACT  
The platelet receptor CLEC-2 is a ligand for the transmembrane protein podoplanin, 
which is present on human lymphatic endothelial cells (HLEC).  Mice lacking CLEC-2 or 
podoplanin display a blood-lymphatic mixing phenotype, possibly due to incomplete 
separation of the developing vessels.  Previous work demonstrated that podoplanin 
mediates polarised migration of HLEC in response to VEGF-C and that platelets inhibit HLEC 
migration. Therefore, the aim of this work was to assess whether the interaction between 
podoplanin and CLEC-2 altered the migration of HLEC.  Transfilter migration assays were 
used to assess the effect platelets and an anti-human podoplanin antibody on HLEC 
migration. 
We found that platelets inhibit VEGF-C mediated HLEC migration in a count-
dependent manner and that crosslinking podoplanin with a specific antibody and an 
appropriate secondary also gave a reduction in HLEC migration.  Crosslinking podoplanin in 
the presence of the Rho kinase inhibitor Y27632 gave no further inhibition of migration.  
Using Y27632 in conjunction with platelets gave a partial recovery in the effect of platelets, 
suggesting platelets require activation of the RhoA signalling pathway to exert their anti-
migratory effects.  
In summary, crosslinking podoplanin with platelets or antibodies inhibits VEGF-C 
mediated HLEC migration and this may be dependent on the RhoA signalling pathway.  
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1. INTRODUCTION 
1.1.  The lymphatic system & lymphangiogenesis 
The lymphatic system is a complex network of vessels whose functions are (i) to 
return tissue fluid exuded from the blood vessels to the circulation; (ii) to absorb lipids in the 
intestinal villi; and (iii) to transport leukocytes and antigen-presenting cells to secondary 
lymphoid tissues as part of the immune response.  Therefore, tissues which are in frequent 
contact with foreign antigens, such as the skin and mucous membranes, have noticeably 
higher numbers of lymphatic vessels.   
The structure and permeability of lymphatic vessels is distinct from that of blood 
vessels.  This is particularly apparent in the lymphatic capillaries, which are formed from a 
single layer of lymphatic endothelial cells (LEC).  LEC have little or no basement membrane 
and loose intercellular junctions, which makes the lymphatic capillaries highly permeable 
and allows leukocytes to enter the lymphatic vessels (1), whereas blood vascular endothelial 
cells (BVEC) have tight intercellular junctions, making them significantly less permeable.  In 
contrast to BVEC, which are supported by pericytes and smooth muscle cells, LEC are only 
stabilised by anchoring filaments (2), which connect LEC to the extracellular matrix and 
dilate the lumen of the lymphatic capillary as interstitial pressure increases, enhancing the 
uptake of tissue fluid (1).  While this structure applies to lymphatic capillaries, the larger 
lymphatic collecting vessels can have smooth muscle cells, continuous interendothelial 
junctions and basement membranes. 
 
 
LEC express several specific markers not found in BVEC but expressed separately by 
some non-endothelial cells (3), including the transcription factor prospero-related 
homeobox 1 (Prox1), vascular endothelial growth factor receptor 3 (VEGFR3) and the 
transmembrane protein podoplanin.  All of these markers have specific roles in lymphatic 
development. 
 The lymphatic system develops once the blood vascular system is established and 
functional.  This occurs at around week 6-7 in human embryonic development and at 
embryonic day (E) 9.5-10.5 in mice (1) when a subpopulation of endothelial cells in the 
cardinal vein begin expressing Prox1, which commits them to the lymphatic lineage (Figure 
1).  In Prox1-deficient embryos, these cells fail to express lymphatic endothelial markers and 
instead retain their blood vascular endothelial phenotype (4).  The result of this deficiency is 
that lymphatic vessels and lymph sacs do not develop (5-7).   
This Prox1-positive subpopulation of cells begin to show a LEC phenotype with an 
increase in the expression of other LEC markers, such as podoplanin and VEGFR3, with a 
simultaneous decrease in BVEC markers, including CD34 and laminin (5).  During this process 
there is a reduction in the vein’s pericyte and smooth muscle coverage (8) that, when 
combined with degradation of the extracellular matrix, allows LEC to access the 
mesenchyme (9).  Vascular endothelial growth factor C (VEGF-C) is synthesised by the 
surrounding mesenchyme (10) and interacts with both  VEGFR2 and VEGFR3, although with 
higher affinity for VEGFR3 (11).  It promotes LEC sprouting and directional migration, leading 
to the formation of primordial lymph sacs (11).  Blocking VEGF-C is known to prevent 
lymphangiogenesis through a failure in LEC migration (12,13).  
 
 
 
Figure 1: Overview of lymphangiogenesis in a mouse model.  At E9.5 cells on one side of the 
cardinal vein begin expressing Prox1, which signals their commitment to the lymphatic 
lineage.  These cells then begin expressing additional LEC markers, including podoplanin and 
VEGFR3, before migrating away from the cardinal vein.  This migration is dependent on VEGF-
C and leads to the formation of the primary lymph sacs.  The blood and lymphatic systems 
separate between E11.5 and E14.5.  This is thought to involve platelet signalling via Syk and 
SLP-76. Adapted from (17). 
 
 
LEC migration is characterised by reorganisation of the actin cytoskeleton, which 
allows lamellipodia to be extended and the edge of the cell to bind to the substratum.  From 
this point the cell body is moved forwards before it detaches from the substratum and the 
tail end of the cell is retracted (14).  VEGF-C is also known to promote LEC proliferation (15), 
required for the growth of lymph sacs and  generation of a network of lymphatic vessels, 
which can be detected throughout the embryo by E14.5 (16). 
Lymphangiogenesis can also occur in a number of pathologies.  It can be associated 
with acute or chronic inflammation, such as at sites of bacterial infection or in rheumatoid 
arthritis (17). In these circumstances macrophages and granulocytes at the inflammatory site 
produce VEGF-C, promoting the generation of lymph vessels (13,17). Lymphangiogenesis 
also occurs during tumour metastasis, particularly in breast and colon carcinomas.  
Metastasis via the lymphatic system is the most common form of metastasis for solid 
tumours (18).  Tumour cells are able to produce lymphangiogenic factors, including VEGF-C, 
which allow the development of peritumoural lymphatic vessels and facilitate lymphatic 
metastasis (19).    
1.2.  Podoplanin 
Podoplanin has recently been identified as a surface receptor on LEC, but has not 
been found on BVEC.  It is a heavily glycosylated small transmembrane protein that is also 
expressed by kidney podocytes, type 1 lung alveolar cells, osteoblasts and epidermal 
keratinocytes (3).  Podoplanin can be detected in the cardinal vein from E11.5 in mice and 
later becomes restricted to Prox1-expressing LEC in the developing lymph sacs (20,21).  
Podoplanin-deficient mice die from respiratory failure shortly after birth and are known to 
 
 
have incomplete formation of lymphatic, but not blood vessels (21,22).  Endothelial loss of 
the T-synthase enzyme, required for the correct O-glycosylation of podoplanin, also leads to 
embryonic and neonatal lethality associated with disorganised and blood-filled lymphatic 
vessels (23). 
Although the role of podoplanin is not yet completely understood, there is 
considerable evidence of its role in regulating cell migration.  Podoplanin can bind through 
its cytoplasmic tail to ezrin/radixin/moesin (ERM) proteins, which connect actin filaments 
and the cell membrane and subsequently activate RhoA GTPases (24).  The Rho GTPases are 
a family of signalling molecules that control a number of cellular processes, including the 
cytoskeletal rearrangements necessary for polarised cell migration.  These proteins can exist 
in both GTP-bound active and GDP-bound inactive states and conversion between these is 
regulated by guanine nucleotide-exchange factors, GTPase-activating proteins and guanine 
nucleotide-dissociated inhibitors (25).  Activated GTPases bind to a range of different 
effector molecules, including Rho kinase, which is associated with the regulation of cell 
contraction and the formation of stress fibres (26).  RhoA signalling has previously been 
shown to be involved in VEGF-induced migration of BVEC (27) and it has recently been 
reported that polarised migration of human lung microvascular LEC requires the regulation 
of RhoA by podoplanin (28).  Moreover, podoplanin upregulation in tumours is associated 
with altered actin cytoskeleton reorganisation and increased metastasis (24), whereas 
siRNA-mediated knockdown of podoplanin causes a dramatic reduction in directional 
migration (28).  These effects appear to be independent of ligand engagement and may 
therefore reflect constitutive signalling from podoplanin.  Whether the binding of a ligand to 
podoplanin alters this signalling remains to be proved.  
 
 
1.3.  Platelets in lymphatic development 
Similar to T-synthase or podoplanin knockouts, mice deficient in SYK, SLP-76 or PLCγ-
2 develop a blood-lymphatic mixing phenotype (29-31).  Together with the identification of 
podoplanin as the endogenous ligand for the platelet membrane protein C-type lectin 
receptor 2 (CLEC-2) (32,33), these studies led to the proposal that correct separation of the 
lymphatic and blood vessels requires interaction between podoplanin on LEC and CLEC-2 on 
platelets, resulting in CLEC-2 signalling through Syk, SLP-76 and phospholipase Cγ2 (PLCγ2).   
CLEC-2 is a type II transmembrane protein primarily expressed by platelets and 
megakaryocytes (34,35), but has also been identified in immune cells such as mouse 
neutrophils (36).  This platelet receptor, which exists on the surface of platelets as a dimer 
(35,37), was first identified as a receptor for the snake venom toxin rhodocytin (34).  CLEC-2 
also mediates tumour cell-induced platelet activation by interacting with podoplanin on the 
tumour cell surface and is known to contribute to tumour metastasis (33,38). 
The cytosolic tail of CLEC-2 contains a conserved YxxL sequence known as a 
hemITAM, preceded by three acidic amino acids (DED).  When a ligand (podoplanin, 
rhodocytin or specific antibodies) binds to the receptor, the tyrosine of the hemITAM motif 
is phosphorylated, creating binding sites for the SH2 domains of the tyrosine kinase Syk (35).  
Once Syk has bound to CLEC-2 it is phosphorylated by Src family kinases, resulting in the 
activation of PLCγ2 and a potent platelet aggregation and secretion response (34).   
CLEC-2 knockout mice die shortly after birth and embryos show haemorrhage, 
oedema and a blood-lymphatic mixing phenotype similar to that seen in podoplanin-
deficient mice.  It has also been noted that the lymphatic vessels in CLEC-2 knockout 
 
 
embryos are more dilated and appear rugged when compared to the same vessels in normal 
embryos (39).  As podoplanin is the only known endogenous ligand for CLEC-2, the 
phenotype of these mice confirmed the hypothesis that the interaction between CLEC-2 and 
podoplanin is required for normal lymphatic development.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Mice lacking proteins associated with CLEC-2 signalling display the same phenotype.  Mice 
deficient in CLEC-2, podoplanin, SLP-76 or Syk all display a blood-lymphatic mixing phenotype.  This is 
thought to be due to incomplete separation of the developing vascular systems.  Adapted from 
(21,22,29,39). 
CLEC-2 -/- 
Blood-lymphatic mixing 
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Podoplanin -/- 
Syk -/- SLP-76 -/- 
 
 
 
1.4. Hypothesis and aims of the project 
Mice deficient in either podoplanin or CLEC-2 develop a blood-lymphatic mixing 
phenotype that suggests the two systems are not properly separating during embryonic 
development (21,39).  In addition to this, previous work has shown that a high number of 
platelets reduce the migration of LEC (Navarro-Núñez et al., unpublished data).  The LEC 
surface protein podoplanin is the only known endogenous ligand for the platelet receptor 
CLEC-2 (34).  Therefore it was hypothesised that the crosslinking of podoplanin would 
prevent LEC migration.  The specific aims of this project were to assess whether (i) platelet-
mediated or (ii) antibody-mediated crosslinking of podoplanin inhibits LEC migration.  This 
was achieved by assessing LEC migration in transfilter assays in the presence of platelets or 
an anti-human podoplanin antibody. 
 
 
 
2. METHODS 
2.1.  Cell culture 
Primary human dermal lymphatic endothelial cells (HLEC) were obtained from 
PromoCell (Heidelberg, Germany).  The cells were maintained in 1% gelatine-coated flasks 
with MV2 basal medium that was supplemented with: 50 μl/ml foetal calf serum, 5 ng/ml 
recombinant human epidermal growth factor, 10 ng/ml recombinant human basic fibroblast 
growth factor, 20 ng/ml insulin-like growth factor (long R3 IGF-1), 0.5 ng/ml recombinant 
human vascular endothelial growth factor 165, 1 μg/ml ascorbic acid and 0.2 μg/ml 
hydrocortisone (PromoCell).  For cell passage HLEC were detached with 0.05% trypsin-EDTA 
(PAA, Yeovil, UK) when confluent, while non-enzymatic dissociation solution (Sigma, Poole, 
UK) was used to prepare cells for experiments. 
2.2.  Preparation of washed human platelets 
Whole blood was obtained from healthy volunteers who had not taken any 
medication affecting platelet function in the previous 10 days.  Informed consent was 
obtained before donation and blood was drawn into 4% sodium citrate (1/9 volume).  To 
further prevent activation of isolated platelets, 10% acid citrate dextrose (ACD: 120 mM 
sodium citrate, 110 mM glucose and 80 mM citric acid) was added to the blood, which was 
centrifuged at 200 g for 20 minutes.  The resulting platelet rich plasma (PRP) was pipetted 
into a clean 50 ml Falcon tube.  2.84 μM prostacyclin was added; the tube was mixed by 
inversion and centrifuged at 1000 g for 10 minutes.  The pellet was resuspended in 1 ml 
modified Tyrode’s buffer (134 mM NaCl, 2.9 mM KCl, 0.34 mM Na2HPO4, 12 mM NaHCO3, 20 
mM HEPES, 1 mM MgCl2; pH 7.3), then 24 ml modified Tyrode’s buffer, 3 ml ACD and 2.84 
 
 
μM prostacyclin were added to the tube, which was centrifuged at 1000 g for a further 10 
minutes.  The pellet was resuspended in 1 ml modified Tyrode’s and the cells were counted 
using a cell counter (Coulter, High Wycombe, UK) before being diluted to the required 
concentration.  Platelets were allowed to rest for at least 30 minutes before the start of an 
experiment.  
2.3.  Flow cytometry 
Flow cytometry was used to confirm the presence of podoplanin on the surface of 
HLEC.  Cells were detached from the flask using a non-enzymatic solution and resuspended 
in sterile PBS (Invitrogen, Paisley, UK).  4x104 HLEC in 75 µl were added to FACS tubes and 
incubated with 2.5 μg/ml of phycoerythrin-conjugated rat anti-human podoplanin (clone NZ-
1.3) or phycoerythrin-conjugated rat IgG2a isotype control (eBioscience, Hatfield, UK) 
following the manufacturer’s instructions.  After the cells were incubated with the respective 
antibodies for 30 minutes in the dark, 300 µl PBS was added to each tube before the samples 
were analysed on a FACSCalibur flow cytometer (BD Bioscience, Oxford, UK) using Cellquest 
with voltage settings as follows: forward scatter (FSC): E-01; side scatter (SSC): 211; both in 
log mode.  Data was collected from 10,000 events for each sample and a gate was applied 
around live cells for analysis. 
An indirect FACS staining approach using the same antibody clone (NZ-1.3) or a rat 
IgG control (R&D Systems, Abingdon, UK) followed by an Alexa Fluor 488 goat anti-rat IgG 
secondary also showed specific podoplanin staining in HLEC.  To determine the saturating 
concentration of the unconjugated NZ-1.3 antibody, 4x104 HLEC in 75 μl were stained with 
serial dilutions of the antibody in PBS to give final concentrations ranging from 5 to 0.15625 
 
 
μg/ml.  Two rat IgG controls were prepared in parallel at final concentrations of 2 or 20 
μg/ml.  The secondary antibody was kept at a fixed concentration of 25 μg/ml.  After 
incubation with the secondary antibody the samples were diluted with 300 µl PBS and 
analysed as above.      
2.4.  Cell migration assay 
Migration assays used 24-well plates with cell culture inserts (BD Biosciences, Oxford, 
UK; 8μm pore size).  To assess the best time point for the experiment, initial assays used 
incubation periods of 24 and 48 hours.  In these preliminary experiments the effect of VEGF-
C on HLEC migration was assessed by adding 0, 150 or 300 ng/ml VEGF-C (R&D Systems) in 
cell culture medium to the lower chamber of the well.  3x104 HLEC in complete culture 
medium were applied to the upper chamber of the insert in a volume of 200 μl.  After 
incubation for the indicated time points at 37 °C and 5% CO2, the VEGF-C solutions and 
medium were removed from both chambers and the inserts were washed with sterile PBS.  
A fixative solution consisting of 2% buffered formalin (Sigma) in sterile PBS with 2 μg/ml 
bisbenzimide (Sigma) was applied to the inserts (700 μl in the lower chamber and 300 μl in 
the upper chamber).  The inserts were incubated at room temperature, protected from light, 
for 15 minutes before the fixative was removed and the inserts washed with PBS.  The 
porous membranes were cut out of each insert and mounted onto a microscope slide using 
Hydromount (National Diagnostics, Georgia, USA), a non-fluorescent mounting medium.  All 
slides were stored in the dark at 4°C until visualisation.  
In later experiments the effect of platelets on HLEC migration in the presence and 
absence of VEGF-C was examined.  HLEC were applied to the insert as before and incubated 
 
 
at 37°C for one hour before washed human platelets were added.  1x104 – 1x108 platelets in 
modified Tyrode’s were added to the filter in volumes of 100 μl.  The same volume of buffer 
was added to non-treated parallel controls.   In separate experiments, to assess whether 
platelet addition might affect HLEC adhesion to the porous membrane, platelets were added 
to the insert immediately after HLEC seeding or an hour later.  This experiment was 
performed in the presence of VEGF-C and the final incubation time was 24 hours.  
The effect of the rat anti-human podoplanin antibody NZ-1.3 on VEGF-C induced 
HLEC migration was also examined.  NZ-1.3 antibody was applied to the insert at a 
concentration of 2 μg/ml and in some wells an anti-rat IgG2a antibody (Biolegend, Bar Hill, 
UK) was also added at different ratios to induce crosslinking.  The negative controls 
contained 2 μg/ml of an irrelevant rat IgG with and without the anti-rat secondary antibody.  
In separate experiments wells were set up with 100 μM of the Rho kinase inhibitor 
Y27632 (Calbiochem, Nottingham, UK) or PBS as a control.  This inhibitor was also used in 
combination with 108 platelets or 2 μg/ml anti-human podoplanin antibody.  The aim of 
these experiments was to determine whether inhibiting a downstream effector of RhoA 
would inhibit VEGF-C mediated HLEC migration and to assess whether Rho kinase was 
involved in the mechanism underlying the effects seen with platelets and the anti-human 
podoplanin antibody.   
2.5.  Microscopy 
The results of the cell migration assay were analysed by visualising the stained HLEC 
nuclei using an inverted fluorescent microscope (Zeiss, Hertfordshire, UK) and counting the 
 
 
number of cells above and below the filter in 15 separate fields per insert.  Percentage 
transmigration was calculated as follows: 
 
 
2.6.  Evaluation of success of podoplanin crosslinking  
2.6.1.  Sample Preparation 
Platelets were isolated from whole blood as outlined above and were diluted in 
modified Tyrode’s solution to give a concentration of 1x109/ml.  Non-enzymatically detached 
HLEC were resuspended in sterile PBS at a concentration of 5x105 cells/ml.  Crosslinking of 
podoplanin was then attempted using either antibodies or platelets.  The cells undergoing 
antibody-mediated crosslinking were incubated with either 10 μg/ml of an anti-human 
podoplanin antibody or rat IgG.  After incubating for 30 minutes on ice an anti-rat secondary 
antibody was added to two of the tubes.  The control sample contained HLEC with PBS.  The 
cells used for platelet-mediated crosslinking were incubated for 30 minutes at 37 °C under 
stirring with washed human platelets or washed platelets that had been fixed in 1% 
formaldehyde.   
Once the samples had been incubated with the appropriate combination of 
antibodies or platelets, sulfo-EGS (Thermo Scientific, Loughborough, UK) was added to each 
sample at a final concentration of 1.5 mM.   This chemical crosslinker was used to stabilise 
any platelet or antibody-mediated crosslinking that had occurred.  The samples were 
incubated at room temperature for 30 minutes before 1 M Tris-HCl was added at a final 
 
 
concentration of 25 mM to quench the reaction between the samples and sulfo-EGS.  The 
samples were incubated for a further 20 minutes at room temperature.  Next, an equal 
volume of 2x ice-cold lysis buffer (50 mM Tris, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 0.5 
mM AEBSF, 1 mM Na3VO4, 5 mM NaF, 1 µg/ml pepstatin A, 5 µg/ml aprotinin, 5 µg/ml 
leupeptin, 1% NP-40) was added to the samples, which were centrifuged for 10 minutes at 
13,000 rpm with the centrifuge set to 4 °C.  The samples were then stored at -20 °C until 
analysis by Western blot at a later date.  
2.6.2.  SDS-PAGE and Western blot 
Proteins in the samples were resolved by 10% polyacrylamide gel electrophoresis 
under reducing conditions.  The stacking buffer used consisted of 0.5 M Tris-HCl at pH 6.8, 
while the resolving buffer was 3 M Tris-HCl at pH 8.8.  32 µl of each sample was mixed with 8 
µl of 5x Laemmli buffer (10% SDS, 25% 2-mercaptoethanol, 50% glycerol, 25% stacking 
buffer, trace Brilliant Blue R).  The samples were boiled for five minutes at 100 °C then 
centrifuged briefly.  10 μl of a molecular weight marker (New England Biolabs, Hitchin, UK) 
was loaded onto the gel, followed by 30 µl of each sample in consecutive wells.  The tank 
was filled with running buffer (25 mM Tris, 192 mM glycine, 0.1% SDS) and run at 100 V for 
approximately 2 hours.  Proteins were then transferred to a PVDF membrane (Biorad, Hemel 
Hempstead, UK) previously soaked in methanol, water and cold transfer buffer (48 mM Tris, 
39 mM glycine, 1.3 mM SDS, 20% methanol) inside a transfer cassette with the membrane 
and gel sandwiched between filters pre-soaked in transfer buffer.  
The transfer cassette was set up with the membrane and gel sandwiched between 
the pre-soaked filters.  The transfer was run at 100 mA for 40 minutes.  After the transfer 
 
 
had completed the gel and filters were discarded.  The membrane was blocked in 10% 
bovine serum albumin (BSA) containing 0.1% sodium azide in TBS-T (200 mM Tris, 1.37 M 
NaCl, 0.1% Tween-100) for an hour.  An anti NZ-1.3 antibody (1/5000 dilution) was prepared 
in 10 ml 10% BSA in TBS-T.  The blocking BSA was removed from the membrane and 
replaced with this antibody solution, which was left on the membrane overnight on a rocking 
platform at 4°C. 
The membrane was then washed three times in TBS-T, for 20 minutes each time on a 
rocking platform.  A 1/10000 dilution of horseradish peroxidase (HRP)-conjugated anti-rat 
antibody (Santa Cruz Biotechnology, Heidelberg, Germany) was prepared in 10 ml TBS-T.  
The membrane was incubated with this antibody solution for an hour at room temperature, 
before being washed as before.  Finally, the membrane was washed briefly with water and 
excess liquid was blotted from the membrane.  1 ml of each solution from an enhanced 
chemiluminescence detection kit (Thermo Scientific, Loughborough, UK) was applied to the 
membrane, left for one minute and excess removed.  The membrane was developed using 
autoradiography with an exposure time of 30 minutes.  
2.7.  Statistics 
The Student’s t-test was used to determine the significance between data sets.  
Where several conditions needed to be compared, an analysis of variance (ANOVA) was 
performed to determine statistical significance. 
 
 
 
3. RESULTS 
 
3.1.  Podoplanin is present on the surface of lymphatic endothelial cells 
When purchased, the HLEC are described as expressing podoplanin on their surface.  
To confirm this before the cells were used in any experiments, flow cytometry was 
performed with the cells stained for podoplanin using both direct and indirect methods.  
Gating around intact cells showed that podoplanin was expressed on the surface of HLEC 
(Figure 3B &D) and that staining with an irrelevant isotype-matched rat IgG showed low 
levels of non-specific staining (Figure 3A & C).  In contrast, when a gate was applied to the 
cell debris the samples incubated with anti-human podoplanin showed a low level of 
podoplanin staining, while incubation with IgG confirmed a low level of background signal 
(Figure 4A-D).  The levels of podoplanin staining were quantified using the mean 
fluorescence intensity of each sample (Figure 5).  The level of fluorescence after indirect 
staining with rat IgG appears high in the cell debris (Figure 5B), but this level of staining was 
consistent with the fluorescence seen in the indirectly stained intact cells and was still much 
lower than the fluorescence seen in the intact samples stained with anti-human podoplanin 
(Figure 5A).      
 
 
 
 
 
A B 
D C 
IgG Anti-podoplanin 
Figure 3: Podoplanin is present on the surface of HLEC.  Direct staining using 
phycoerythrin-conjugated IgG showed a low level of background staining (A) but using a 
phycoerythrin-conjugated anti-human podoplanin antibody showed the presence of 
podoplanin on the surface of HLEC (B).  Similarly, indirect staining of HLEC with rat IgG 
showed a low level of non-specific stining (C), while staining with anti-human 
podoplanin showed the presence of podoplanin on HLEC (D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Podoplanin is not present in the cell debris.  Using the same samples as previously, 
the cell debris was gated to determine whether podoplanin was present.  Neither of the 
directly stained samples (A and B) showed any podoplanin in the cell debris.  The indirect 
samples (C and D) showed some low levels of staining, which may be due to the background 
noise in the samples.  The alternative explanation is that there were fragments of HLEC 
membrane containing podoplanin in the debris.  
C D 
A B 
IgG Anti-podoplanin 
 
 
 
 
 
A 
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Figure 5: Quantification of podoplanin staining in intact HLEC and cell debris.  The mean 
fluorescence intensity was determined in both intact HLEC and cell debris. (A)  The intact 
cells showed an increase in fluorescence when staining was performed with anti-human 
podoplanin.  (B) The cell debris showed low levels of fluorescence with both rat IgG and anti-
human podoplanin.  While the indirect IgG sample appears to have a high level of 
fluorescence this is actually similar to the background fluorescence seen in the intact cells 
(MFI = 13.91 vs 10.82) and is still much lower than the fluorescence seen with podoplanin 
staining in intact HLEC. n = 1 
 
 
 
3.2.  Platelets reduce VEGF-C mediated migration of lymphatic endothelial 
cells 
Having confirmed that podoplanin was present on HLEC, modified Boyden chamber 
assays were performed to assess transmigration of HLEC.  This assay allows quantitation of 
cell migration through a porous membrane and reagents can be added to the assay to assess 
their effect on migration.  In this study, VEGF-C was used in the assay as it has been shown 
to promote directional HLEC migration (12,13).  The assay was characterised to determine 
the most appropriate incubation time and concentration of VEGF-C.  The incubation times 
used in these preliminary experiments were 24 and 48 hours and the lower chamber of the 
wells contained 0, 150 or 300 ng/ml VEGF-C diluted in normal cell culture medium.  These 
concentrations (corresponding to 0, 10 and 20 nM respectively) were selected as they were 
close to the dissociation constant (KD, ligand concentration at which 50% of receptors are 
occupied) of the VEGFR-2 and VEGFR-3 receptors (Table 1), which are both receptors for 
VEGF-C (11).  Additionally, a previous report showed that 15 nM VEGF-C is within the 
maximal proliferation response range for both HUVEC and MEC (microvascular endothelial 
cells) and is near the peak migratory response for these cells (40).   
At 24 hours, VEGF-C increased the migration rate in a concentration-dependent 
manner, while at 48 hours HLEC migration was similar in all wells (Figure 6), which was 
probably due to both VEGF-C and HLEC reaching equilibrium.  Therefore, it was decided that 
for future experiments an incubation time of 24 hours would be used as the assay loses 
sensitivity to VEGF-C at 48 hours.  Preliminary experiments (Navarro-Núñez et al., 
 
 
unpublished data) showed that platelets inhibit HLEC migration.  Therefore, the 
experimental conditions had to give a high level of migration in the absence of platelets to 
allow a decrease to be detected.  The data obtained in these experiments suggested that 
300 ng/ml VEGF-C would give a percentage migration of approximately 40% without 
platelets, making any decrease in migration possible to identify, whilst being different from 
the migration seen without VEGF-C. 
 
Ligand Receptor KD (M) Reference 
hVEGF-C hVEGFR-2 2.2 x 10-8 Mäkinen et al., 2001 
hVEGF-C hVEGFR-3 0.44 x 10-8 Mäkinen et al., 2001 
Table 1: Dissociation constants (KD) for VEGF-C at its known receptors.  VEGF-C 
is known to bind to both VEGFR-2 and VEGFR-3, but has been shown to have a 
higher affinity for VEGFR-3 (Mäkinen et al., 2001).  VEGFR-2 and VEGFR-3 KD 
values for VEGF-C are shown.  150 ng/ml and 300 ng/ml VEGF-C correspond to 
9.68 x 10-9 and 1.94 x 10-8 M, respectively. These concentrations are close to the 
KD values of VEGFR-3 and VEGFR-2 for VEGF-C. 
 
 
 
 
The effect of human platelets on HLEC transmigration in the presence or absence of 
300 ng/ml VEGF-C was assessed by performing cell migration assays with differing numbers 
of platelets applied to the upper well of the chamber.   HLEC were added in a volume of 200 
µl and allowed to settle for an hour before the addition of platelets or modified Tyrode’s 
solution to exclude a potential effect of platelets on attachment of HLEC to the membrane.  
The number of platelets used in each well varied from 104-108 in a volume of 100 µl.  A 
healthy adult has approximately 1.5 - 4 x 107 platelets in 100 μl blood, so the platelet counts 
used here were not excessive.  This experiment confirmed that platelets inhibit HLEC 
Figure 6: Characterisation of the transfilter migration assay: Cell culture inserts with 8 μm pores were 
placed into the wells of 24-well plates.  The lower chambers of the wells were filled with complete 
culture medium containing 0 ng/ml, 150 ng/ml or 300 ng/ml VEGF-C.  3 x 104 HLEC in a volume of 200 
μl were added to the filter and the wells were incubated for 24 or 48 hours.  After incubation, the 
porous membranes were washed, fixed, stained and mounted.  Percentage migration was calculated in 
fifteen fields by dividing the number of cells counted in the bottom chamber by the total number of 
cells counted.  Error bars represent the standard deviation of two independent experiments. 
 
 
migration and showed that this was specific to VEGF-C mediated migration (Figure 7A & B).  
A two-way analysis of variance (ANOVA) confirmed that the addition of platelets to the assay 
was significantly inhibiting migration (P = 0.001) and that this effect was only significant in 
the presence of the chemokinetic VEGF-C (P = 0.001).  These data suggest that the presence 
of platelets alters the migratory potential of HLEC in response to VEGF-C.  At the two highest 
platelet counts, the migration levels seen with and without VEGF-C were similar (Figure 7B), 
suggesting that the basal rate of migration was not affected by platelets.        
It was suggested that the addition of platelets may affect the viability and/or 
adhesion of the HLEC.  To test this, the transmigration assays were repeated with 108 
platelets added either immediately after HLEC or after the cells had been incubated for an 
hour.  Analysis of the filters showed that adding platelets at t=0 hours or t=1 hour had the 
same inhibitory effect on HLEC migration through the filter (Figure 8A).  In addition to 
calculating the percentage of migration, the average number of cells on each filter was also 
recorded.  This showed that there was no significant difference between the number of cells 
on each filter, regardless of treatment (Figure 8B), suggesting that platelets were not 
preventing the HLEC adhering to the filter or increasing cell death.  Although adding platelets 
immediately after HLEC did not alter percentage migration or the number of cells on each 
filter, future experiments retained the hour-long incubation period to maintain continuity 
throughout the study.
 
 
 
Figure 7: Platelets inhibit VEGF-C mediated migration of HLEC.  Cells were applied to the filter and 
incubated for an hour at 37 °C before the addition of platelets, which were prepared in a volume of 
100 μl.  The lower chamber of the well contained 300 ng/ml VEGF-C or cell culture medium.  (A) 
Percentage migration of HLEC with the addition of different numbers of platelets.  Migration in wells 
containing 300 ng/ml VEGF-C was inhibited by the addition of platelets (P = 0.001), but the same was 
not true in wells without VEGF-C.  (B) Percentage migration of HLEC plotted as a percentage of the 
basic level of migration in the absence of VEGF-C and platelets.  Error bars on both graphs are the 
standard deviation of four experiments. 
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Figure 8: Time of platelet addition does not affect the transmigration assay.  The lower chamber of 
the wells contained 300 ng/ml VEGF-C and HLEC were applied to the filter as in previous experiments.  
100 μl of platelets (108 cells) was added either immediately after HLEC or an hour later.  100 μl 
modified Tyrode’s buffer was added to the non-treated wells. (A) The different addition times did not 
affect the level of migration through the filter (P > 0.05). (B) There was no significant difference in the 
average number of cells counted on each filter (P > 0.05).  Error bars on both graphs represent the 
standard deviation of three experiments. 
B 
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3.3.   Anti-human podoplanin antibody alone does not inhibit migration 
The migration assays above showed that the interaction between platelets and HLEC 
inhibited the migration of HLEC.  The platelet receptor CLEC-2 is known to bind to 
podoplanin, which is present on the surface of HLEC, so it was hypothesised that this 
interaction may be responsible for the change in HLEC migration.  To test this, an anti-
human podoplanin antibody (clone NZ-1.3) was used in the transfilter migration assay.  
Before this, however, the saturating concentration of the antibody was determined by flow 
cytometry.  HLEC were incubated on ice with concentrations of anti-human podoplanin 
ranging from 0.15625 µg/ml to 5 µg/ml.  The negative controls for this experiment were 
HLEC with either 2 µg/ml or 20 µg/ml rat IgG.  After this first incubation period, 25 µg/ml 
Alexa 488-conjugated anti-rat was added to each of the tubes, which were incubated on ice 
for a further 30 minutes.  The samples were diluted with PBS before analysis. 
 
Staining with IgG showed similarly low levels of non-specific staining at both 2 µg/ml 
and 20 µg/ml (Figure 9A & B).  As the concentration of anti-human podoplanin antibody was 
increased, the level of podoplanin staining also increased (Figure 9C).  There was little 
difference between the median fluorescence at 0.625, 2.5 and 5 µg/ml, although there was a 
slight decrease at 1.25 µg/ml.  Therefore, it was decided that the saturating concentration of 
the antibody was around 2.5 µg/ml and that future experiments would use a concentration 
of 2 µg/ml.  Higher concentrations of antibody were incubated with HLEC to confirm this 
result and as expected there was no further increase in staining of podoplanin.   
 
 
 
 
Figure 9: Titration of anti-human podoplanin antibody.  HLEC were incubated with varying 
concentrations of anti-human podoplanin or rat IgG.  A gate was applied to intact HLEC prior to 
analysis.  Incubating cells with IgG showed a low level of background staining at (A) 2 μg/ml 
and (B) 20 μg/ml.  (C) Median fluorescence increased with increased concentration of 
antibody.  Fluorescence was similar for antibody concentrations of 0.625, 2.5 and 5 μg/ml, 
suggesting that saturation was between 0.625 and 2.5 μg/ml. 
0.15625 µg/ml 
0.3125 µg/ml 
0.625 µg/ml 
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The anti-human podoplanin antibody used in this study (NZ-1.3) is described in the 
literature as a blocking antibody that interacts with the podoplanin domains involved in 
CLEC-2 binding (41).  A transmigration assay was performed to determine whether this 
antibody alone would inhibit VEGF-C mediated HLEC migration and assess if the antibody 
could abrogate platelet-CLEC-2 binding and alter the effect of platelets on HLEC migration 
that was seen at 24 hours.  Anti-human podoplanin antibody was added 30 minutes after 
seeding of HLEC and platelets were added after an additional 30 minutes to ensure full HLEC-
antibody interaction.   
 
The anti-human podoplanin antibody alone did not prevent HLEC migration (Figure 
10), suggesting that podoplanin engagement by monomeric antibody is not sufficient to alter 
migration.  While the migration with rat IgG alone appears lower, this is not statistically 
significant (P > 0.05) and is similar to the level of migration observed in non-treated wells in 
previous experiments.  As expected, platelets inhibited HLEC migration and the combination 
of rat IgG and platelets produced a similar effect.  Interestingly, the antibody only partially 
inhibited the effect of platelets.   
 
 
 
 
 
 
* 
Figure 10: Effect of anti-human podoplanin on HLEC migration.  Anti-human podoplanin antibody or 
rat IgG were added to the filter 30 minutes after HLEC, while platelets were added after a further 30 
minutes incubation.  The lower chamber of the wells contained 300 ng/ml VEGF-C in cell culture 
medium.  Anti-human podoplanin alone did not alter percentage migration, but partially reversed the 
effects of platelets (P < 0.05).  However, there was still a significant inhibition in HLEC migration (P < 
0.05) compared to the control sample.  Error bars are standard deviation of at least two experiments: n 
= 2 for IgG, anti-podoplanin and IgG + 10^8 platelets; n = 3 for all other conditions. 
* 
+ 10^8 platelets n = 2 
* P < 0.05 
* * * 
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3.4. Crosslinking of podoplanin reduces the migration of HLEC 
 
The previous experiment showed that anti-human podoplanin binding to HLEC was 
not enough to alter migration.  Given that CLEC-2 is present on the platelet surface as a 
dimer (Hughes et al., 2010), we hypothesised that further crosslinking of podoplanin may be 
necessary to induce functional effects. 
 
We assessed the effect of a crosslinking strategy combining the anti-human 
podoplanin and an anti-rat secondary in the transmigration assay.  Initially, different 
primary:secondary ratios of 1:1, 1:7.5 and 1:15 were tested to determine the optimal assay 
conditions, keeping the anti-human podoplanin at 2 µg/ml in all cases.  The primary to 
secondary antibody ratio of 1:15 produced a greater inhibitory effect (Figure 11), so was 
used for the remaining experiments. 
 
As seen in previous experiments, neither anti-podoplanin nor rat IgG alone had any 
effect on percentage migration (Figure 11).  Combining the rat IgG with the anti-rat 
secondary did not reduce HLEC migration compared to the non-treated control, but, 
incubating HLEC with both anti-human podoplanin and anti-rat inhibited HLEC migration.  
This suggests that crosslinking of podoplanin leads to the inhibition of HLEC migration. 
 
 
 
 
 
 We aimed to biochemically confirm that podoplanin is crosslinked by both 
platelet binding and antibody-mediated methods.  HLEC were incubated with either 
rat IgG or anti-human podoplanin in the absence or presence of the secondary anti-
rat IgG, or with washed platelets or fixed platelets before chemical crosslinking with 
sulfo-EGS.  The samples were analysed by SDS-PAGE and anti-podoplanin Western 
blot.  The resulting image showed a band at around 40 kDa, detecting podoplanin 
(Figure 12).  It was anticipated that crosslinked podoplanin would appear as another 
band of around 80 kDa.  However, after antibody-mediated crosslinking the only 
extra bands detected were those showing the heavy and light chains of the 
immunoglobulins.  Therefore, podoplanin crosslinking could not be proved in this 
** 
Figure 11: Titration of anti-rat secondary antibody.  HLEC were incubated with 2 μg/ml rat IgG or 
anti-human podoplanin.  The anti-rat secondary antibody was added at ratios of 1:1, 1:7.5 and 
1:15.  Incubation with rat IgG gave similar levels of migration, regardless of the amount of 
secondary antibody used.  In contrast, when anti-human podoplanin was combined with anti-rat, 
migration decreased.  The greatest effect was with a ratio of 1:15 (P < 0.01).  Error bars, where 
applicable, represent the standard deviation of two experiments. * P < 0.05 and ** P < 0.001 vs 
non-treated HLEC (NT). 
IgG + anti-rat Anti-podo + anti-rat 
* * ** 
* P < 0.05 
** P < 0.01 
  
 
 
experiment.   Although the platelet-mediated crosslinking did not produce a band 
that would correspond to crosslinked podoplanin, it gave another band at 
approximately 50 kDa.  This may be associated with podoplanin signalling, but 
further experiments would be required to confirm this point. 
Figure 12: Podoplanin is present in HLEC but cannot be chemically crosslinked by sulfo-
EGS.  All lanes of the gel showed a band at around 40 kDa, which is podoplanin.  The 
dark band in the samples incubated with anti-human podoplanin or rat IgG (60 kDa) 
represents the antibody heavy chain, while the bands above are thought to be non-
specific signals as they also appeared with the IgG treatment.  The antibody light chains 
are also visible at the bottom of the gel (27 and 32 kDa).  The sample that was incubated 
with washed human platelets has a faint band at 50 kDa.  It is not clear what this 
represents, but it may be associated with podoplanin signalling. 
 
 
 
3.5. Crosslinking of podoplanin gives no further inhibition of HLEC 
migration in the presence of Y27632 
Knowing that crosslinking of podoplanin inhibits HLEC migration, we assessed the 
effect of a Rho kinase inhibitor, Y27632, on HLEC migration.  Anti-human podoplanin was 
applied to the filter 30 minutes after HLEC.  This was followed by anti-rat after a further 30 
minute incubation.  Finally, after HLEC had been incubated with the antibodies, 100 µM 
Y27632 was added to the filter.  The lower chamber of the wells contained 300 ng/ml 
VEGF-C.  The non-treated control contained HLEC with PBS as this the diluent used to 
prepare both the antibodies and Rho kinase inhibitor.  Y27632 inhibited HLEC migration at 
a level similar to that of the combined anti-podoplanin and anti-rat antibodies (Figure 13).  
Combining the inhibitor with the antibodies had no additional effect: the decrease in 
migration was the same as that seen with the antibodies alone.    
 
 
 
 
Figure 13: Crosslinking podoplanin does not give any further inhibition of migration in the 
presence of Y27632.  Anti-human podoplanin antibody was added to HLEC and incubated 
for 30 minutes before the secondary antibody was added.  After a further 30 minute 
incubation, 100 μM of the Rho kinase inhibitor Y27632 was applied to the filter.  Y27632 
alone inhibited HLEC migration, as did the antibody-mediated crosslinking of podoplanin.  
However, when the two treatments were combined there was no additive effect.  Error bars 
represent the standard deviation from three experiments. * P < 0.05 compared to non-
treated control (NT).  There was no significant difference between migration with Y27632, 
crosslinking antibodies or the combination of both treatments. 
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* * * 
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3.6. Inhibition of Rho kinase reduces platelet-mediated inhibition of 
migration 
Finally, the Rho kinase inhibitor Y27632 was used alongside platelets in the transfilter 
migration assay.  HLEC were applied to the filter and 100 µM Y27632 was added 30 minutes 
later.  After a further 30 minutes, 108 platelets were added to the filter.  300 ng/ml VEGF-C 
was added to the lower chamber of the well as the effect of platelets was found to be 
specific to VEGF-C mediated migration.  As expected, platelets significantly inhibited HLEC 
migration (Figure 14) and Y27632 also inhibited migration, although to a lesser extent.  
When the platelets and Rho kinase inhibitor were combined, there was no further inhibition 
of migration than that seen with Y27632 alone.   
Figure 14: Combining platelets and Y27632 results in a partial recovery of HLEC migration.  As in 
earlier experiments, both the Rho kinase inhibitor Y27632 and platelets inhibit the migration of 
HLEC, although the data shows that platelets have a more profound effect.  When the inhibitor and 
platelets were combined there was still an inhibition of migration, but it was less pronounced than 
with platelets alone. Error bars are the standard deviation of three independent experiments.  * P < 
0.05 compared to 10^8 platelets.  
n = 3  
 * 
* P < 0.05 
+ anti-rat 
 
 
4. DISCUSSION 
4.1.  Summary of results 
The results from this project indicate that the interaction between platelets and HLEC 
causes a reduction in the migratory potential of HLEC and that this may be through the 
interaction of podoplanin and CLEC-2.  Cell migration assays showed that a high number of 
platelets inhibit VEGF-C mediated HLEC migration and that adding platelets to the filter 
immediately after HELC does not have a significant effect.  Crosslinking of podoplanin with 
the NZ-1.3 antibody and an anti-rat secondary also inhibits HLEC migration, while the NZ-1.3 
antibody alone does not inhibit migration.  The antibody alone partially blocks the effect of 
platelets.  The Rho kinase inhibitor Y27632 nullified the effects of both platelets and 
crosslinking antibodies on HLEC migration.   
 
4.2.  Platelets reduce VEGF-C mediated migration of HLEC 
Mice deficient in either podoplanin or CLEC-2 develop a blood-lymphatic mixing 
phenotype, which is believed to be due to incomplete separation of the blood and lymphatic 
vessels (21,39).  Human platelets are able to inhibit the migration of HLEC and platelets from 
CLEC-2 knockout mice allow a partial recovery from this effect (Navarro-Núñez et al., 
unpublished data).  The transfilter migration experiments confirmed that a high number of 
human platelets will inhibit HLEC migration, suggesting that platelets alter HLEC signalling.  
This alteration in signalling could be through the interaction of podoplanin and CLEC-2, 
which was examined further in later experiments.   These experiments also showed that the 
effect of platelets was specific to VEGF-C mediated migration.  This may be due to an 
 
 
interaction between podoplanin and VEGF-C signalling pathways within the HLEC, but 
further experiments would be required to prove this theory.  
 
VEGF-C acts on the VEGFR-3 receptor and is known to promote both migration and 
proliferation of HLEC (11).  It is found in the mesenchyme of areas of lymphatic development 
(10) and is thought to be essential for lymphangiogenesis.  In the transfilter migration assay, 
the inhibitory effect of platelets was only observed in wells containing VEGF-C.  It has been 
suggested that the platelets in the assay may have been metabolising the VEGF-C.  However, 
this is unlikely as the HLEC were incubated with VEGF-C for an hour before the addition of 
platelets, meaning there was sufficient time for VEGF-C signalling to occur.  In addition to 
this, when platelets were added to the filter immediately after HLEC the result of the assay 
was no different and the platelets still inhibited HLEC migration.     
 
This second experiment also proved that platelets were not affecting the viability or 
adhesion of the HLEC.  The average number of cells on each filter was similar regardless of 
treatment, proving that platelets neither prevent HLEC adhesion nor promote cell death.  
This also supports the hypothesis that platelets are changing the signalling within HLEC 
rather than reducing of the number of adherent cells, which could result in a lower 
percentage migration.   
 
 
 
4.3.  Anti-human podoplanin antibody alone does not inhibit HLEC 
migration 
Having shown that platelets reduced the migration of HLEC, an anti-human 
podoplanin antibody was used to determine whether it was the interaction between CLEC-2 
and podoplanin that was causing this change in migration.  The NZ-1.3 antibody alone had 
no effect on HLEC migration, indicating that podoplanin ligand engagement is not sufficient 
to alter signalling.  The addition of the same concentration of antibody partially reversed the 
effect of platelets in this assay, suggesting that the antibody was not entirely blocking the 
CLEC-2 binding site of podoplanin, allowing platelets to bind and exert their anti-migratory 
effect.  It is possible that platelets were able to bind to HLEC because the antibody used was 
not truly a blocking antibody as had been stated in the literature (41).  Further experiments, 
including an assessment of CLEC-2 – podoplanin binding would have to be performed in 
order to confirm this. 
 
4.4.   Crosslinking of podoplanin inhibits HLEC migration 
Although the transfilter experiments had shown that the NZ-1.3 antibody alone could 
not inhibit HLEC migration, we assessed whether crosslinking podoplanin may have an 
inhibitory effect on migration.  The assay was characterised by determining the optimal ratio 
of NZ-1.3 to anti-rat secondary antibody.  An antibody ratio of 1:15 was found to have the 
greatest inhibitory effect.  These conditions were then used in an experiment comparing the 
effect of NZ-1.3 with and without the anti-rat secondary.  This confirmed that crosslinking of 
podoplanin inhibits HLEC migration, although the change in migration was less pronounced 
 
 
than that seen with platelets.  This data suggests that the crosslinking of podoplanin by 
antibodies alters podoplanin signalling.  It is possible that this change in signalling prevents 
the cytoskeletal rearrangements necessary for migration to occur, but this could not be 
tested during the project.   
  
We attempted to crosslink podoplanin using antibodies or platelets with sulfo-EGS as 
the chemical crosslinker, but this experiment did not produce the expected result.  This is 
most probably due to the sulfo-EGS itself, which has a spacer arm distance of 16.1 Å.  On 
reflection, this is probably not wide enough to stabilise crosslinked podoplanin molecules.  
Although this experiment did not show evidence of podoplanin crosslinking there was a 
band of unknown origin on the Western blot that could be of interest.  This faint band was 
seen in the sample containing HLEC and washed platelets and is slightly heavier than 
podoplanin, at approximately 50 kDa.  It is possible that this unidentified band is involved in 
podoplanin signalling, but more experiments would be needed to confirm this.  The first 
experiment that should be performed is to repeat the platelet-mediated crosslinking in the 
presence of staurosporine.  This would inhibit any protein kinases present in the sample and 
may, therefore, show whether the unknown band is due to podoplanin phosphorylation or 
the interaction of podoplanin with a small signalling protein. 
 
 
 
 
 
4.5.   Crosslinking of podoplanin gives no further inhibition of HLEC 
migration in the presence of Y27632 
Podoplanin is known to associate with ERM proteins, which connect the actin 
cytoskeleton to membrane proteins (24).  Podoplanin signalling has also been associated 
with activation of the Rho GTPase family of proteins, which are signalling molecules involved 
in the cytoskeletal reorganisation that is required for polarised cell migration.  Y27632 is an 
inhibitor of Rho kinase, a downstream effector of RhoA.  Y27632 inhibited HLEC migration, 
but the effect was not as strong as that seen with 108 platelets. This shows that Rho kinase 
does have a role in migration of HLEC.  When Y27632 was combined with the crosslinking 
antibodies the observed migration was the same as that with the 1:15 ratio of antibodies.  
This lack of any further effect suggests that the effect of the antibody crosslinking strategy 
specifically blocks podoplanin signalling, leading to Rho kinase activation instead of a non-
specific side effect.  Although Rho kinase is implicated in HLEC migration, RhoA has several 
other downstream effectors.  Y27632 only targets one of these: Rho kinase.  Therefore, it 
would be sensible to repeat this experiment with an inhibitor that targets RhoA itself, such 
as C3 transferase and compare the degree of inhibition with that seen with platelets.  
   
4.6.  Inhibition of Rho kinase reduces platelet-mediated inhibition of 
migration 
When Y27632 was used in a transfilter assay alongside 108 platelets, there was no 
further inhibition than that demonstrated by Y27632 alone.  One potential explanation for 
this is that platelets may require activation of Rho kinase to allow them to inhibit HLEC 
migration, but this would need to be confirmed in future experiments.   
 
 
 
4.7.  Conclusions and future directions 
The hypothesis underlying this project was that crosslinking of podoplanin would 
prevent the migration of HLEC.  The specific aims were to assess the effect of (i) platelet-
mediated and (ii) antibody-mediated crosslinking on HLEC migration.  The data outlined 
above demonstrates that platelets inhibit VEGF-C mediated HLEC migration.  Similarly, the 
crosslinking antibodies inhibited HLEC migration.  Taken together, these results suggests that 
platelet CLEC-2 crosslinks podoplanin molecules upon binding, which leads to an alteration 
in signalling within the HLEC.  To confirm the requirement for both CLEC-2 and podoplanin, 
platelets from CLEC-2 knockout mice and lymphatic endothelial cells from podoplanin-
deficient mice could be studied.  
 
The data confirms the requirement for VEGF-C in lymphangiogenesis, as HLEC 
migration was low in the absence of VEGF-C.   As the effect of platelets is specific to VEGF-C 
mediated migration it is possible that podoplanin crosslinking might modify VEGF-C 
signalling.  However, more work would have to be undertaken to determine whether this is 
the case.  
 
The mechanism underlying the inhibition of migration still needs to be determined.  
Initial experiments performed as part of this project suggest a role for Rho kinase, although 
there may be an additional compensatory mechanism.  As Rho kinase, which we inhibited 
with Y27632, is only one effector of RhoA, the transfilter assays could be repeated in the 
presence of C3 transferase, a Rho inhibitor.  The level of Rho activation at various time 
 
 
points during the assay could also be assessed to confirm that crosslinking is affecting RhoA 
activation. 
In summary, we have shown that crosslinking of podoplanin with platelets or 
antibodies reduces VEGF-C mediated migration of HLEC and that the effect of platelets is 
dose-dependent.  Although the mechanism is still unclear, data from this project and 
previously published work (24,28) indicates a role for RhoA in podoplanin signalling. 
 
 
 
 
 
 
 
 
 
 
 
REGULATION OF THE PLATELET COLLAGEN RECEPTOR GPVI AND ITS SHEDDASE 
ADAM10 BY TETRASPANIN MEMBRANE MICRODOMAINS 
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ABSTRACT 
Tetraspanins are transmembrane proteins that are thought to have a number of roles in the 
organisation of cell surface proteins.  The platelet collagen receptor GPVI has been identified 
as a component of tetraspanin microdomains.  Similarly, its sheddase, ADAM10, has been 
shown to be tetraspanin-associated and previous work has found that ADAM10 is regulated 
by a specific subgroup of tetraspanins, known as the 8-Cys tetraspanins.  Therefore, the aim 
of this work was to determine whether ADAM10 activation altered its localisation within the 
tetraspanin microdomain.  We also wanted to confirm whether ADAM17 was associated 
with CD9 and assess whether the megakaryocyte-like HEL cell line would be a suitable model 
in which to study tetraspanin regulation of GPVI cleavage by ADAM10. 
We found that ADAM10 was associated with platelet tetraspanins regardless of its activation 
state.  From our data, ADAM17 does not appear to be associated with CD9 in platelets, but 
this may be due to low ADAM17 expression on these cells.  HEL cells are not a suitable for 
studying GPVI cleavage and ADAM10 regulation by tetraspanins.  Attempts to knockdown 
ADAM10 with siRNA were not successful and GPVI staining was lower than in platelets.  
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1. INTRODUCTION 
1.1. Tetraspanins 
The tetraspanins are a family of cell surface glycoproteins that are found in a number 
of species, including humans, mice, fruit flies plants and some multicellular fungi.  Humans 
are known to have 33 different tetraspanins, many of which appear to be expressed in most 
cell types (42).  However, the expression of some tetraspanins is restricted to certain cell 
types, for example CD53 is expressed specifically by leukocytes (42).   The exact function of 
tetraspanins is still being determined, but it is believed that they play a role in several areas, 
including i) ligand binding of associated proteins; ii) modulation of signalling; iii) modulation 
of trafficking; and iv) regulation of proteolytic processes (42).  Tetraspanins function through 
interactions with a number of specific partner proteins and as tetraspanins are involved in a 
range of different processes, the proteins that they associate with are also diverse.  The 
proteins known to associate with tetraspanins can be divided into four groups: integrins and 
other adhesion molecules; proteins with immunoglobulin domains; ectoenzymes; and 
intracellular signalling molecules (43,44).   
 
As well as interacting with partner proteins, tetraspanins are also able to interact 
with each other in what has been termed the “tetraspanin web”, also known as tetraspanin 
microdomains (45).  These complex microdomains consist of clusters of tetraspanins and 
their partner proteins and are distinct from lipid rafts (46).  The formation of microdomains 
is thought to be the reason behind the discrepancy between data obtained with anti-
tetraspanin antibodies and knockout mice.  While experiments with anti-tetraspanin 
antibodies have shown significant effects on cell behaviour and suggested an essential role 
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for tetraspanins, several of the knockout mice have unexpected phenotypes, although 
others have striking phenotypes (47).  One notable example is the CD9 knockout mouse: CD9 
is highly expressed in most cell types, but the only phenotype the knockout displays is a 
defect in sperm-egg fusion (48).  It has been suggested that knocking out a specific 
tetraspanin does not produce an obvious phenotype because the microdomain remains 
intact, but antibodies disrupt the partner proteins in the microdomain, so have a more 
profound effect on cell function (47).  Another difficulty in tetraspanin research is that each 
cell type can have many different tetraspanins, which may function in a compensatory 
manner if one is mutated or deleted.  This has been shown to be the case with CD9 and 
CD81, which share about 50 % of their sequences.  If CD81 is overexpressed in CD9-deficient 
eggs, then there is a recovery in the defective sperm-egg fusion previously seen with these 
cells (49).  Similarly, CD9/CD81 double knockout mice develop pulmonary emphysema and 
secretory cell metaplasia (50), which is not seen in either of the single knockout mice. 
 
Figure 15: Structure of tetraspanins.  Tetraspanins are small cell surface 
proteins with four transmembrane domains and two extracellular loops.  
The extracellular domains differ in size, with the second being larger 
than the first.  Tetraspanins can be categorised according to the number 
of cysteine residues in the large extracellular loop. 
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Tetraspanins are relatively small proteins and are characterised by four 
transmembrane domains and two extracellular domains (42), as shown in Figure 15.  Both 
the N- and C-terminals of tetraspanin molecules are cytoplasmic and these cytoplasmic 
sections of tetraspanins usually consist of less than twenty residues (51).  The two 
extracellular domains differ in size and the structure of the large extracellular loop can be 
divided into constant and variable regions.  The constant region consists of three α-helices, 
while the variable region contains the majority of the sites that are known to be necessary 
for interactions with other proteins (52).    Tetraspanins also have a number of conserved 
cysteine residues that are involved in the formation of disulphide bonds and the tetraspanin 
superfamily can be subcategorised according to the number of cysteine residues present in 
the large extracellular loop, which can be four, six, seven or eight (52).  Of particular interest 
in this project are those tetraspanins that have eight cysteine residues, known as the “8-Cys” 
tetraspanins.  There are six 8-Cys tetraspanins: Tspan5, Tspan10, Tspan14, Tspan15, Tspan17 
and Tspan33.  This group of tetraspanins is believed to interact with a disintegrin and 
metalloproteinase (ADAM) 10 as Tspan33 knockout mice have reduced levels of ADAM10 on 
their red blood cells (Haining and Tomlinson, unpublished data).  While ADAM10 levels on 
platelets from these mice were normal it is possible that other 8-Cys tetraspanins are able to 
compensate for the loss of Tspan33 in platelets.  In addition to this, the overexpression of 8-
Cys tetraspanins has been found to promote trafficking to the plasma membrane and to 
increase levels of active ADAM10 (Collier and Tomlinson, unpublished data).  This association 
with tetraspanins may have implications for ADAM10’s target proteins, including the platelet 
receptor glycoprotein (GP) VI (53,54).   
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1.2. Platelets, tetraspanins and GPVI 
Platelets play an essential role in haemostasis but also have a role in arterial 
thrombosis, which can result in myocardial infarction and stroke.  Anti-platelet therapies are 
often used in the treatment of these conditions, but not all patients respond well to these 
drugs and some develop severe bleeding, which can be fatal.  Therefore, understanding how 
platelet receptors are regulated may reveal new therapeutic strategies for treating 
myocardial infarction and stroke.   
 
Mice deficient in the platelet tetraspanins CD151 or Tspan32 display a mild bleeding 
phenotype, which seems to be due to a defect in signalling via αIIbβ3, the major platelet 
integrin (55,56).  The fact that this phenotype is mild suggests that there are other platelet 
tetraspanins involved in haemostasis.  Initial experiments on the CD9 knockout mouse did 
not show a platelet phenotype using the standard platelet function tests, such aggregation in 
the response to various agonists, but intravital microscopy showed that these mice failed to 
embolise thrombi after ferric chloride injury (57,58).  Similarly, CD63 knockout mice 
displayed a mild platelet phenotype with the only difference detected being a slight in vitro 
hyperaggregation in response to a range of agonists (57,58).  In addition to this, Tspan9 
knockout platelets have been shown to have a mild defect in spreading and aggregation in 
response to GPVI-induced activation (Haining and Tomlinson, unpublished data). 
 
  Currently, fifteen tetraspanins have been identified on platelets.  Most of these 
proteins are expressed at relatively low levels, with the notable exception of CD9, which is 
the second most highly expressed protein on the platelet surface (59).  Of these fifteen 
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tetraspanins, the presence of five (CD9, CD63, CD151, Tspan9 and Tspan32) has been 
confirmed using antibody-mediated methods (60,61).  The remaining ten tetraspanins were 
identified in a proteomics study (59), but these associations have not yet been verified.   
 
The platelet immunoglobulin superfamily protein GPVI has been shown to be 
associated with tetraspanin microdomains (61).  GPVI is a receptor for both collagen and 
laminin and is specifically expressed by platelets and megakaryocytes.  It forms complexes 
with the Fc receptor γ-chain (FcRγ) via a salt bridge and this complex formation is necessary 
for GPVI to bind collagen.  Through its binding of collagen, GPVI plays an important role in 
the activation of platelets.  After the vascular endothelium has been damaged, platelets are 
able to transiently adhere to the vessel through the interaction between von Willebrand 
factor (vWF) and GPIb-IX-V.  This allows GPVI to bind to collagen, even though the receptor 
has a relatively low affinity for collagen.  The interaction between GPVI and collagen 
stimulates an ITAM-mediated signalling cascade that results in the activation of platelets 
(62).    
 
As GPVI has a role in the activation of platelets and their eventual formation of a 
thrombus, it has been suggested that targeting GPVI could produce effective anti-platelet 
therapies.  One suggestion has been to reduce the levels of intact GPVI on the platelet 
surface and one interaction that could be explored further is the action of ADAM10 on GPVI.  
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1.3. ADAM10 and ADAM17 
ADAM10 and ADAM17 are members of the ADAM superfamily of proteins, which are 
multidomain proteins that have both disintegrin and metalloproteinase domains (63).  
ADAM proteins have a prodomain that is necessary for correct folding of the immature 
enzyme (64), but also maintains the protein in an inactive state.  In order for the protein to 
be activated, the prodomain has to be cleaved, which is primarily by furin and PC7 (65).  
ADAM proteins function as ectodomain sheddases, cleaving the extracellular region 
of target proteins.  In addition to GPVI, ADAM10 has a number of other important targets, 
including epidermal growth factor (66), Notch (67) and amyloid precursor protein (68).  
Defective ADAM10 activity has previously been associated with Alzheimer’s disease and 
cancer (66,69) and may also have a role in inappropriate thrombus formation through its 
targeting of GPVI.  ADAM10 has been shown to be associated with tetraspanins (43,70) and 
Tspan12 overexpression has been shown to increase levels of mature ADAM10 (71).  In 
addition to the effect of Tspan12 on ADAM10, previous work has also shown that 
overexpression of the 8-Cys tetraspanins increases the amount of mature ADAM10 (Collier 
and Tomlinson, unpublished data).  It is believed that the association between ADAM10 and 
8-Cys tetraspanins is necessary for the trafficking of immature ADAM10 from the 
endoplasmic reticulum to the cell surface (Figure 16).   
 
The current hypothesis is that when ADAM10 is associated with a tetraspanin it is 
chaperoned from the endoplasmic reticulum through the Golgi network, where furin and 
PC7 cleave its prodomain, to its destination at the cell surface.  Without the tetraspanin 
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association, levels of mature ADAM10 at the cell surface are likely to be reduced.  In 
platelets, this would result in more intact GPVI, allowing platelet activation through its 
binding to collagen.  In theory, if surface levels of ADAM10 are reduced then there will be 
elevated levels of GPVI, potentially allowing excessive platelet activation.  However, GPVI 
cleavage tends to occur when platelets are activated and ADAM10 is not the only protease 
cleaving GPVI, as it has been shown that ADAM17 and at least one other protease are also 
able to do this (54).  Another complication arises from the possibility that tetraspanins may 
negatively regulate ADAM10, keeping it inactive whilst at the cell surface to prevent 
excessive cleavage of GPVI.   
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While ADAM10 is known to be tetraspanin-associated, there is currently some 
debate as to whether ADAM17 is also associated with tetraspanin enriched microdomains.  
A recent publication has described the association of ADAM17 with CD9 on the surface of 
both leukocytes and endothelial cells (72), which contradicts previous studies (70,71).  Data 
obtained from knockout mice has shown that ADAM17 is also to cleave GPVI in vitro and it is 
interesting to note that the same study also detected GPVI cleavage in ADAM10/ADAM17 
double knockout mice in vivo, which suggests that there is at least one other protease acting 
Figure 16: Proposed role of the interaction between ADAM10 and tetraspanins.  When associated 
with tetraspanins, immature ADAM10 is successfully transported through the Golgi to the cell surface, 
where it becomes associated with the tetraspanin microdomain.  Once ADAM10 is within the 
microdomain, the prodomain is cleaved.  However, if ADAM10 does not associate with a tetraspanin, it is 
unable to be transported from the endoplasmic reticulum, leading to a reduction in mature ADAM10 at the 
cell surface.  Adapted from Haining and Tomlinson, unpublished. 
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on GPVI (54).  However, another group claim that ADAM10 is the primary GPVI sheddase and 
did not show a role for ADAM17 in GPVI cleavage (53).   
 
1.4. Hypothesis and aims of the project 
As GPVI is known to be a target of ADAM10 it is possible that through understanding 
the localisation of these proteins within tetraspanin microdomains a new therapeutic angle 
for inhibiting platelets will become apparent.  It was hypothesised that the localisation of 
ADAM10 and GPVI within tetraspanin microdomains changes when ADAM10 is activated.  
Therefore, the aims of this project were: 
1. To determine whether activation of ADAM10 and cleavage of GPVI by ADAM10 
alters the localisation of these proteins on platelets  
2. To confirm whether ADAM17 is associated with CD9 on platelets 
3. To assess whether the HEL megakaryocyte-like human erythroleukaemia cell line 
can be used as a model system for studies involving tetraspanins, ADAM10 and 
GPVI 
 
10 
 
 
2. MATERIALS AND METHODS 
2.1. Cell culture 
Human erythroleukaemia (HEL) cells were maintained in RPMI medium (PAA, 
Yeovil, UK) that was supplemented with 10% foetal calf serum, 2 mM L-glutamine 
and 100 units/ml penicillin and 0.1 mg/ml streptomycin (PAA).  These suspension 
cells were kept at a concentration of 1 x 106/ml or less, so were split 1:10 every 3-4 
days.  A549 cells, a human alveolar epithelial cell line, were maintained in Dulbecco’s 
modified eagle medium (DMEM; PAA) containing 10% foetal calf serum, 1 % L-
glutamine and 1 % penicillin-streptomycin.  A549 cells were detached for passage or 
experiments by scraping or using 0.05% trypsin-EDTA (PAA). 
2.2. Preparation of washed human platelets 
Whole blood was taken from healthy volunteers who had given informed 
consent and had not taken any medication that would affect platelet function.  
Blood was drawn into 4% sodium citrate (1:9 volume) and to prevent platelet 
activation 10% acid citrate dextrose (ACD: 120 mM sodium citrate, 110 mM glucose 
and 80 mM citric acid) was added to the blood.  The blood was centrifuged at 200 
xg for 20 minutes.  10 μg/ml prostacyclin was added and the sample was 
centrifuged for 10 minutes at 1000 xg.  The pellet was resuspended in warm 
modified Tyrode’s buffer (134 mM NaCl, 2.9 mM KCl, 0.34 mM Na2HPO4, 12 mM 
NaHCO3, 20 mM HEPES, 1 mM MgCl2; pH 7.3) containing 5 mM glucose.  A further 
24 ml Tyrode’s was added with 3 ml ACD and 10 μg/ml prostacyclin.  The platelets 
11 
 
were centrifuged for a further 10 minutes at 1000 xg.  The pellet was resuspended 
in 5 ml modified Tyrode’s buffer and counted using a cell counter (Coulter, High 
Wycombe, UK).   
 
2.3.  Flow Cytometry 
2.3.1. Platelets 
Flow cytometry was used to assess whether W7 (Calbiochem, Nottingham, 
UK) and N-ethyl maleimide (NEM; Calbiochem) were activating ADAM10, which 
would be demonstrated by a decrease in intact GPVI.  1 x 108 washed human 
platelets were incubated for an hour at 37 °C with 2 mM NEM, 150 μM W7 or 
DMSO in a final volume of 1 ml.  5 μl of each treatment was transferred to FACS 
tubes and incubated with 10 μg/ml anti-human CD9 (clone 1AA2, gift from Prof 
Leonie Ashman), anti-human GPVI (clone: 204-11; gift from Prof Masaaki Moroi) or 
negative control MOPC IgG monoclonal antibody (Sigma, Poole, UK) for 30 minutes 
at room temperature.  1 mM EGTA in Tyrode’s buffer was added to each tube and 
unbound antibody removed by centrifuging at 1000 x g for 5 minutes.  Anti-mouse 
IgG-FITC was then incubated with the platelets for 30 minutes.  Samples were 
diluted with 500 μl FACS buffer (0.2 % bovine serum albumin and 0.02 % NaN3 in 
PBS) before analysis on a FACSCalibur flow cytometer (BD Bioscience, Oxford, UK) 
using Cellquest.  A gate was applied around intact cells and data collected from 
10,000 events.    
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2.3.2. HEL cells 
1 x 106 HEL cells were incubated at 37 °C for an hour with 1 mM NEM, 150 
μM W7 or the vehicle controls (ethanol or DMSO).  Each sample was divided 
between FACS tubes and indirect staining using MOPC or GPVI (204-11) antibodies, 
followed by an anti-mouse IgG secondary, was performed.  Samples were diluted 
with 500 μl FACS buffer containing 2 μg/ml propidium iodide (Sigma) before 
analysis.  A gate was applied around live cells and data was collected from 5,000 
events. 
Analysis of ADAM10 knockdown in HEL cells was by flow cytometry.  An 
indirect staining approach for MOPC, CD9 (1AA2) and ADAM10 (clone 163003, R&D 
Systems, Abingdon, UK) was used.  The secondary antibody was the same as in the 
previous experiments.  The samples were diluted in 500 μl FACS buffer and analysed 
as above. 
In later experiments assessing ADAM10 knockdown, a direct staining 
approach was used to stain cells for ADAM10.  The FITC-conjugated ADAM10 and 
isotype control antibodies (R&D Biosystems) were used at a concentration of 1.25 
μg/ml and FACS analysis was as described above. 
 
2.3.3. A549 cells 
 A549 cells were used as a positive control in the siRNA-mediated ADAM10 
knockdown experiments.  1.5 x 105 cells were stained for MOPC or ADAM10 
(163003).  Initially this was using an indirect approach, but in later experiments 
13 
 
directly conjugated antibodies were available, so a direct staining approach was 
used.  The cells were diluted in FACS buffer with 2 μg/ml propidium iodide before 
being analysed on the FACSCalibur.   
  
2.4. Biotinylation and immunoprecipitation of human platelets 
Initial experiments assessed the effect of ADAM10 activation by W7 on the 
localisation of ADAM10 and GPVI.  50 μl protein G sepharose beads (Invitrogen, 
Paisley, UK) were combined with 2.5 μg of MOPC, anti-human ADAM10 (163003), 
anti-human CD9 (1AA2) or anti-human GPVI (204-11).  The beads were incubated 
overnight at 4 °C on a rotator.   
Washed human platelets resuspended in a volume of 2.5 ml Tyrode’s buffer 
(with 2 mM CaCl2) and were incubated with DMSO or 150 μM W7 for an hour at 37 
°C.  Platelets were treated with 1 mg/ml sulfo-NHS-LC-biotin (Thermo Scientific, 
Loughborough, UK) and incubated for 30 minutes at room temperature before the 
reaction was quenched with 125 mM glycine.  The platelets were pelleted and 
resuspended in 2.5 ml PBS before being divided between five 1.5 ml tubes and lysed 
with an equal volume of 2x Brij 97 lysis buffer (2 % Brij97, 20 mM Tris at pH 7.5, 150 
mM NaCl, 2 mM CaCl2, 2 mM MgCl2, 0.02 % NaN3) containing 1:100 protease 
inhibitor cocktail (P8340; Sigma).  20 μl protein G sepharose was added to each 
tube, which were rotated at 4 °C for 60 minutes to pre-clear the lysates.   
The debris was pelleted and the supernatants pooled.  50 μl of each 
supernatant was added an equal volume of 2x non-reducing sample buffer.  The 
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rest was divided between tubes containing the antibody-coupled beads, which had 
been washed in Triton X-100 lysis buffer.  The samples were then incubated for a 
further 75 minutes at 4 °C.  After this incubation the samples were washed four 
times with ice-cold Triton X-100 lysis buffer before being transferred to a clean 1.5 
ml tube.  All lysis buffer was aspirated before 50 μl 2x non-reducing sample buffer 
was added to each tube.  The samples were stored at - 20 °C and analysed by SDS-
PAGE and Western blotting at a later date.  This experiment was repeated with a 
slight change in the incubation conditions: the platelets were resuspended in 
Tyrode’s buffer and 2 mM CaCl2 was then added to the W7-treated sample only. 
In later experiments we assessed whether ADAM17 was associated with CD9.  
The protein G sepharose beads were coupled to 2.5 μg MOPC, anti-human ADAM10 
(163003), anti-human ADAM17 (clone 111633; R&D Systems) or anti-human CD9 
(1AA2).  The platelets were biotinylated as before, but half were lysed in 2x Brij97 
with the remainder lysed in 2x Triton X-100.  The immunoprecipitations were 
performed as described above, but the washes used either Brij97 or Triton X-100, 
depending on which buffer the cells had been lysed in.  After washing, 50 μl 2x non-
reducing sample buffer was added to each tube.  The samples were kept at -20 °C 
until analysis by Western blot at a later date. 
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2.5.  SDS-PAGE and Western blot 
Proteins were resolved using a 4-12% gradient gel (NuPAGE, Paisley, UK) 
under non-reducing conditions.  Samples were boiled for 5 minutes and centrifuged 
briefly before being loaded onto the gel.  2.5 μl molecular weight biomarker (New 
England Biolabs, Hitchin, UK) in 17.5 μl 2x non-reducing sample buffer was loaded 
into the first lane of the gel and 1 μl biomarker in 19 μl buffer was put in the last 
lane.  All empty lanes contained 20 μl non-reducing sample buffer.  The tank was 
filled with running buffer (50 mM MOPS, 50 mM Tris base, 0.1% SDS and 1 mM 
EDTA; NuPAGE) and run at 125 V for approximately 2 hours.  
 
The gel was removed and soaked in transfer buffer (25 mM Tris, 190 mM 
glycine, 20% methanol) for 30 minutes, while the PVDF Immobilon FL membrane 
(Millipore, Watford, UK) was wetted with methanol before being soaked in transfer 
buffer.  The transfer chamber was set up with the gel and membrane sandwiched 
between pre-soaked filters and foam pads.  The transfer was run at 30 V for 90 
minutes.  After transfer, the membrane was blocked with TBS (20 mM Tris, 137 mM 
NaCl, pH 7.6) containing 3 % bovine serum albumin (BSA) and 0.1 % sodium azide 
for an hour at room temperature.  The primary antibody, either anti-human CD9 or 
anti-human ADAM10, was prepared in 10 ml of  TBS-T (20 mM Tris, 137 mM NaCl, 
0.1 % Tween, pH 7.6) containing 3 % BSA and 0.1 % sodium azide.  The membrane 
was incubated with the antibody overnight at 4 °C. 
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The membrane was washed three times in high salt TBS-T (20 mM Tris, 500 
mM NaCl, 0.1 % Tween) for 10 minutes.  The secondary antibodies, anti-mouse 680 
(Li-Cor, Cambridge, UK) with or without neutravidin (Perbio, Cramlington, UK), were 
prepared at a 1/10,000 dilution in TBS-T containing 3 % BSA and 0.1 % sodium azide.  
The membrane was incubated with this solution for 90 minutes at room 
temperature before being washed for 5 x 5 minutes with high salt TBS-T.  A final 
wash with TBS was then performed.  The membrane was blotted dry and analysed 
using an Odyssey infrared imaging system (Li-Cor).  
 
2.6.  siRNA knockdown of ADAM10 
8 x 105 HEL cells and 1.5 x 105 A549 cells were applied to 6-well plates in a 
volume of 2 ml antibiotic-free medium.   To make the HEL cells adherent and thus 
potentially more amenable to transfection, they were treated with 6.2 ng/ml phorbol 
12-myristate 13-acetate (PMA; Calbiochem) for 24 hours.  2.5 μl of 4 μM control or 
ADAM10 siRNA (ID 1005; Applied Biosystems, Warrington, UK) was mixed with 167.5 
μl Optimem (GIBCO, Paisley, UK) and separately, 7.5 μl RNAiMAX (Invitrogen) was 
added to 67.5 μl Optimem.  Both solutions were then incubated at room 
temperature for 10 minutes, after which 30 μl of RNAiMAX solution was added to 
each siRNA preparation.  After incubating for a further 10 minutes, 200 μl siRNA-
RNAiMAX solution was added to the cells, giving a final siRNA concentration of 10 
nM.  The cells were incubated with this solution for four hours at 37 °C before it was 
replaced with antibiotic-free medium.  After incubating at 37 °C for 72 hours, the 
cells were detached using 0.05 % trypsin-EDTA, transferred to FACS tubes and 
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indirectly stained for MOPC or ADAM10 before being analysed by flow cytometry.  
When this experiment was repeated a direct staining approach was used.  FITC-
conjugated anti-human ADAM10 antibody (R&D Systems) was used and a FITC-
conjugated isotype-matched mouse IgG (R&D Systems) was used as the control.  As 
before, analysis was by flow cytometry.   
 
Finally, a time course experiment was performed.  2 x 106 HEL cells were 
treated with 6.2 ng/ml PMA before being transfected with control or ADAM10 siRNA 
as before.  The cells were then incubated for 48, 72 or 96 hours before being 
analysed by flow cytometry using a direct staining approach. 
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3. RESULTS 
3.1. W7 and NEM induce GPVI shedding in platelets 
W7 and NEM are both believed to activate ADAM10 and thus induce GPVI 
shedding from the platelet surface (53,54).  The pro-domain of ADAM10 contains a 
cysteine switch, which consists of a thiol that inhibits metalloproteinase activity.  This 
thiol is modified by NEM, resulting in restoration of ADAM10’s metalloproteinase 
activity.  Ectodomain shedding by ADAMs is also regulated by calmodulin, which is 
associated with the cytoplasmic domain of GPVI (73).  W7, a calmodulin inhibitor, is 
thought promote GPVI shedding by inhibiting the association between calmodulin 
and GPVI.  This has been shown to be dependent on ADAM10 (54). 
 To establish a GPVI shedding assay in our lab, we assessed the effect of these 
drugs on human platelets by comparing GPVI levels in platelet rich plasma (PRP) and 
washed platelets that had been treated with 150 μM W7, 2 mM NEM or a vehicle 
control.  After the samples had been incubated with the appropriate treatment for 
an hour, indirect staining for GPVI and the positive control CD9, for which there is no 
evidence of shedding, was performed before the samples were analysed by flow 
cytometry.  Gating around intact cells showed that incubating platelets with either 
W7 or NEM resulted in an almost complete loss of GPVI from the cell surface (Figure 
17).  There was also a reduction in GPVI staining in the washed platelets that had 
been incubated with the vehicle control, which results from the formation of a 
secondary shoulder peak on the FACS plot.  This may have been due to the presence 
19 
 
of calcium, which was chelated during platelet preparation to reduce the possibility 
of platelet activation, but was added back to allow ADAM10 to function.  There also 
appeared to be a mild increase in CD9 staining in samples treated with NEM or W7, 
which is more apparent when the median fluorescent intensities are expressed as a 
percentage of the staining in the PRP sample (Figure 18).  In this experiment, NEM 
gave a 25 % increase in CD9 compared to PRP, while W7 gave a 50 % increase in CD9 
staining (Table 2).  In an earlier experiment, which did not include PRP, W7 more than 
doubled CD9 staining compared to washed platelets treated with DMSO.  In this 
particular experiment, NEM did not appear to increase CD9 staining.  This suggests 
that one consequence of metalloprotease activation might be to render the small 
non-cleaved CD9 more accessible to antibody staining, due to the shedding of larger 
proteins that might normally reduce access of the relatively large antibody molecule. 
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Table 2: W7 and NEM treatment increase CD9 staining in human platelets.  Median 
fluorescent intensities were normalised before being expressed as a percentage in CD9 
staining in the PRP or washed platelet controls.  In both experiments, W7 increased CD9 
staining, while NEM only increased CD9 staining in the second experiment. 
Treatment – experiment 1 Percentage staining vs washed platelets 
2 mM NEM 93 % 
150 µM W7 278 % 
Treatment – experiment 2 Percentage staining vs washed platelets 
2 mM NEM 125 % 
150 µM W7 154 %  
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Figure 17: W7 and NEM reduce GPVI levels on platelets.  Washed platelets were incubated with 
150 μM W7, 2 mM NEM or a vehicle control for an hour at 37 °C.  Indirect FACS staining for CD9, 
GPVI and an irrelevant control (MOPC) was then performed.  Both the PRP and vehicle samples 
showed GPVI staining, which was lost after treatment with W7 or NEM.  The washed platelets also 
showed a shoulder peak, which is thought to be due to calcium in the Tyrode’s buffer.  While CD9 
was used as a positive control, the drugs appeared to increase CD9 staining. N = 1 for PRP and n = 2 
for all other samples, traces are representative of both experiments.  
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3.2. ADAM10 association with tetraspanin microdomains does not 
appear to be affected by its activation 
ADAM10 is known to associate with tetraspanins (43) and it is possible that 
tetraspanins keep it in an inactive conformation.  It was hypothesised that when 
ADAM10 is activated it is released from the tetraspanin microdomain, allowing it to 
cleave GPVI.  Washed human platelets were incubated for an hour at 37 °C with 
DMSO or 150 μM W7, which had previously been shown to increase GPVI cleavage.  
Platelets were then surface biotinylated and immunoprecipitations (IPs) for ADAM10, 
Figure 18: Quantification of CD9 and GPVI staining in human platelets.  The median fluorescence 
intensity was determined in all samples.  This was then normalised using the control staining in each 
sample before being expressed as a percentage of the CD9 or GPVI staining seen in the PRP.  The 
washed platelets that had been incubated with the vehicle showed a 35% decrease in GPVI staining 
compared to PRP, while there was a 95% decrease after W7 treatment and a 98% decrease after 
treatment with NEM.  In contrast, the CD9 staining increased after treatment with W7 or NEM (by 
50% and 25%, respectively). n = 1 
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CD9, GPVI and a control were performed.  The samples were analysed by SDS-PAGE 
and Western blots with neutravidin (which detects biotin), or antibodies against CD9 
and ADAM10. 
These biochemical experiments showed that ADAM10 was associated with 
tetraspanins in both its active and inactive forms.  This was apparent in both the 
neutravidin (Figure 19A) and CD9 (Figure 19B) Western blots.  The neutravidin blot 
showed a pattern of bands in both the ADAM10 and CD9 IPs, which is characteristic 
of tetraspanins and their associated proteins.  The bands in the W7-treated samples 
appeared darker than in the DMSO samples and we suspected a discrepancy in 
protein concentration.  However, a commercially available protein assay (DC protein 
assay, BioRad, Hemel Hempstead, UK) confirmed that there was an equal amount of 
protein in the samples (data not shown).  This suggests that W7 treatment makes 
platelets more amenable to surface biotinylation.  In the CD9 blot there was a dark 
band at approximately 25 kDa, which represents CD9.  This was visible in both the 
CD9 and ADAM10 IPs, confirming that ADAM10 is associated with CD9 in platelets.  
These samples were also analysed by ADAM10 Western blot (Figure 19C), which 
showed a band at 70 kDa in both the ADAM10 and CD9 IPs.  This band represents 
ADAM10, therefore confirming the association between these two proteins.     
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Figure 19: ADAM10 and CD9 are associated in human platelets.  Washed human platelets 
were incubated with either DMSO or 150 µM W7 before being biotinylated.  
Immunoprecipitations for ADAM10, CD9, GPVI and a control were then performed. (A) The 
neutravidin blot showed similar band patterns in the ADAM10 and CD9 IPs regardless of 
treatment.  This band pattern is characteristic of tetraspanins and their associated proteins. 
(B) The 25 kDa band in the CD9 blot represents CD9.  This band can be detected in CD9 and 
ADAM10 IPs from platelets treated with DMSO or W7. (C) The ADAM10 blot showed a band 
at approximately 70 kDa in the CD9 and ADAM10 IPs.  This represents ADAM10 in the 
samples and treatment with W7 gave the same result as incubation with DMSO.  
Neutravidin and CD9 blots are representative of three separate experiments. 
B 
C 
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These biochemical experiments had 2 mM CaCl2 in the Tyrode’s buffer that 
the platelets were resuspended in, but it was later determined that the presence of 
calcium may have been inducing ADAM10 activation and some cleavage of GPVI in the 
control samples, which was confirmed by flow cytometry (Figure 17).  Therefore, it is 
important to note that ADAM10 may have been active in the DMSO control, so it is 
difficult to draw conclusions from this data.  To overcome this problem, the experiments 
were repeated with CaCl2 added to the W7-treated samples only.  The neutravidin blots 
from these experiments also showed that ADAM10 is inactive ADAM10 is associated with 
tetraspanins (Figure 20).   
None of these blots showed the association between CD9 and GPVI, which has 
been demonstrated previously in this lab (61).  This is believed to be due to developing 
the blots using an infra-red imaging system rather than chemiluminecence.  The platelet 
number used here is also lower than in the Protty study. 
A 
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Figure 20: ADAM10 is associated with tetraspanins when in its inactive state.  
Platelets were incubated with DMSO without CaCl2, before being biotinylated.  
Immunoprecipitations for ADAM10, CD9, GPVI and a control were then 
performed.  The neutravidin blot showed the same band pattern as that 
observed in the earlier experiments where the DMSO control contained CaCl2, 
thus confirming that inactive ADAM10 is associated with tetraspanin 
microdomains. 
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3.3. ADAM17 does not appear to be associated with CD9 in platelets 
There is currently some debate as to whether ADAM17 is associated with the 
tetraspanin CD9.  A recent paper has shown the association in both leukocytes and 
endothelial cells (72), but this contradicts previous studies that claimed there was no 
association between ADAM17 and CD9 (70,71).  In addition to this, proteomics 
studies have found ADAM10 sequences associated with tetraspanins, but not 
ADAM17 sequences (74).  It is, however, possible that this association was not 
detected as ADAM17 levels were too low on the cells used for the study.  As CD9 is 
relatively abundant on platelets, we examined whether ADAM17 is associated with 
CD9 in platelets.  Washed human platelets were biotinylated and control, ADAM10, 
ADAM17 and CD9 IPs were performed in both Brij97 and Triton X-100 lysis buffers.  
The samples were analysed by SDS-PAGE and neutravidin Western blot. 
The neutravidin blot showed similar band patterns in the ADAM10 and CD9 
IPs that were performed in Brij97 lysis buffer (Figure 21A), consistent with the 
localisation of these molecules to tetraspanin microdomains on platelets.  In 
contrast, the ADAM17 IP did not show the same band pattern, suggesting that it is 
not associated with CD9 in platelets.  When the exposure on the blot was increased, 
a band at approximately 130 kDa became visible (Figure 21B). This could be ADAM17, 
based on its expected molecular weight.  However, it is possible that ADAM17 was 
not immunoprecipitated in this experiment, either because the expression level is 
low compared to ADAM10 or due to a failure of the ADAM17 antibody to effectively 
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bind ADAM17.  Therefore, this preliminary experiment should be repeated in future 
with a positive control ADAM17 lysate.  The samples that had been prepared in 
Triton X-100 did not have the same band pattern as this stronger detergent severed 
the interactions between the different proteins in the tetraspanin microdomain.  
Therefore, only the primary protein, ADAM10 or CD9, was visible.   
 
A 
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3.4. W7 and NEM induce GPVI cleavage in HEL cells  
Another aim of this project was to assess whether the HEL cell line would be a 
suitable model for studying ADAM10 and GPVI.  Since human platelets are not 
amenable to genetic modification, such a cell line model would allow ADAM10 
cleavage of GPVI to be studied in the context of a tetraspanin siRNA knockdown or 
Figure 21: ADAM17 does not appear to be associated with CD9 in human platelets.  Human 
platelets were biotinylated and immunoprecipitations for ADAM10, ADAM17, CD9 and an 
irrelevant control were performed in both Brij97 and Triton X-100 lysis buffers.  The samples were 
analysed by SDS-PAGE and neutravidin Western blot.  (A) Both the ADAM10 and CD9 IPs prepared 
in Brij97 showed a band pattern that is characteristic of tetraspanins, confirming that ADAM10 is 
tetraspanin-associated.  The same was not true of ADAM17, suggesting it is not associated with 
tetraspanins.  (B) The ADAM17 IP performed in Brij97 showed a single band at 130 kDa, which is 
believed to be ADAM17.  Blots are representative of two separate experiments.   
B 
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overexpression.  The first stage in this assessment was to ensure that W7 and NEM 
were activating ADAM10, as shown by a decrease in intact GPVI.  As with the 
equivalent experiment in platelets, this was done by incubating the cells at 37 °C for 
an hour with the appropriate drug or a vehicle control and determining GPVI levels 
by flow cytometry.  
 
The flow cytometry data showed that both 150 μM W7 and 2 mM NEM 
lowered GPVI levels in HEL cells (Figure 22), although GPVI staining intensity was low 
compared to that on platelets (Figure 17), suggesting that HEL cells are not an ideal 
model in which to study GPVI.  The median fluorescent intensities were normalised 
before being expressed as a percentage of the GPVI staining in the control sample.  
This quantification showed that 2 mM NEM gave an 80% reduction in GPVI staining 
and 150 μM W7 gave a 40% decrease, suggesting that in this experiment NEM was 
more effective than W7 at activating ADAM10, as shown by the reduction in intact 
GPVI. 
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Figure 22: W7 and NEM induce GPVI cleavage in HEL cells.  HEL cells were 
treated with 150 μM W7, 2 mM NEM or a vehicle control for an hour at 37 °C.  
The cells were then stained for GPVI and an irrelevant control using an indirect 
method. (A) Flow cytometry data showed a slight shift in the GPVI peak in both 
the W7- and NEM-treated samples. (B) When the FACS data was quantified 
using the median fluorescence intensity W7 was shown to reduce GPVI by 40%, 
while NEM reduced GPVI by approximately 80% (compared to the control 
sample). 
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3.5. siRNA-mediated knockdown of ADAM10 is not effective in HEL cells 
Having shown that W7 and NEM could activate ADAM10 in HEL cells we 
attempted to knockdown ADAM10 using an siRNA-mediated method.  Cells were 
pre-treated with 6.2 ng/ml PMA to make them adherent, more megakaryocyte-like, 
as previously demonstrated (75), and potentially more readily transfectable with 
siRNA, since suspension cells were not transfectable in preliminary experiments 
(data not shown).  The following day the cells were transfected with 10 nM of 
control or ADAM10 siRNA or left untransfected.  Three days after transfection the 
cells were stained for ADAM10 and a control (MOPC) using an indirect staining 
method.  Flow cytometry was then used to determine what proportion of ADAM10 
remained on the cell surface.  A549 cells were transfected with the same siRNAs as 
a positive control.  This cell line was chosen as siRNA knockdown of ADAM10 in 
these cells had been successfully used by other members of the group (Khan and 
Tomlinson, unpublished data).   
 
The non-transfected HEL cells and those that had been transfected with 
control siRNA had similar levels of ADAM10 (Figure 23).  However, the cells that had 
been transfected with ADAM10 siRNA showed only around a 50 % decrease in 
ADAM10 expression (Figure 23B).  Examination of the histogram suggested that this 
weak knockdown was probably due to poor transfection efficiency, since a small 
ADAM10-low population was evident in addition to a larger population with normal 
ADAM10 levels.  In contrast, when the A549 cells were transfected with the 
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ADAM10 siRNA there was a 95 % decrease in the amount of ADAM10 present on 
the surface of the cells (Figure 24B).  
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Figure 23: Transfection with ADAM10 siRNA does not significantly reduce ADAM10 
on the surface of HEL cells.  HEL cells were treated with 6.2 ng/ml PMA to make 
them more adherent and were transfected with control or ADAM10 siRNA the 
following day or left untransfected.  After 72 hours the amount of ADAM10 on the 
cells was assessed by flow cytometry, using an indirect staining method.  (A) The 
FACS plots from this experiment do not clearly show a leftward shift of the ADAM10 
peak, but there is a shoulder peak forming, which is likely to be the cells in which 
ADAM10 knockdown has been successful.  (B) The amount of ADAM10 after 72 hours 
was quantified and expressed as a percentage of the amount detected in the non-
transfected cells.  The control siRNA did not alter the amount of ADAM10.  The 
specific ADAM10 siRNA reduced the amount of ADAM10 by 50 %.  Error bars 
represent the standard deviation of two separate experiments. 
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Figure 24: Transfection with ADAM10 siRNA reduces ADAM10 on the surface of A549 cells.  
A549 cells were transfected with control or ADAM10 siRNA and analysed by flow cytometry 
72 hours after transfection.  (A) The FACS plot clearly shows the peak representing ADAM10 
shifting left after transfection with ADAM10 siRNA.  (B) The percentage of ADAM10 after 
transfection was quantified using the median fluorescence intensity.  The specific siRNA gave 
a reduction of approximately 95 % in this cell line.  Error bars represent the standard 
deviation of two separate experiments. 
  
A 
B 
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 It is possible that analysing the extent of ADAM10 knockdown 72 hours after 
transfection was the reason behind the relatively low knockdown levels.  At 72 hours the 
majority of the ADAM10 protein may not have been removed or, alternatively, the HEL cells 
were beginning to re-express ADAM10 by 72 hours.  To determine whether this was 
affecting the experiment, we carried out a time course study with flow cytometry performed 
at 48, 72 and 96 hours after transfection.  Cells were pre-treated with PMA as in the 
previous experiment and the transfection used the same siRNA construct.  After the 
appropriate incubation period cells were stained for ADAM10 and a control.  The amount of 
ADAM10 in the cells transfected with specific siRNA was calculated using the median 
fluorescence intensity and expressed as a percentage of the cells transfected with control 
siRNA. 
 The different incubation times did show a difference in ADAM10 expression, but the 
reduction was not enough to be considered a successful knockdown.  After 48 hours there 
was a 20 % reduction in ADAM10, which became a 10 % reduction after 72 hours (Figure 25).  
At 96 hours there was a marginal increase in ADAM10 expression.  Overall the reduction in 
ADAM10 in this experiment was lower than that seen previously. 
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 In summary, there was not a significant reduction in ADAM10 at 72 hours post-
transfection and the extent of ADAM10 knockdown was not improved when the HEL cells 
were analysed at 48 and 96 hours.  This contrasts to the A549 cells, which gave over 90 % 
knockdown of ADAM10 with the same siRNA.  Together with the low endogenous GPVI 
expression levels, these data suggest that HEL cells are unlikely to make a good model 
system in which to study the effects of tetraspanin knockdown on ADAM10 expression and 
GPVI shedding.  
 
Figure 25: siRNA knockdown of ADAM10 is affected by incubation time.  HEL cells were 
transfected with ADAM10 or control siRNA and ADAM10 expression was determined by flow 
cytometry at 48, 72 and 96 hours after transfection.  The median fluorescence intensity from the 
FACS plots was normalised and expressed as a percentage of the control sample from the 
respective time point.  There was a 20 % reduction in ADAM10 after 48 hours, which was lost over 
the following time periods to give a 10 % reduction in ADAM10 after 72 hours and a slight increase 
in ADAM10 at 96 hours post-transfection.  n = 1. 
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4. DISCUSSION 
 
4.1. Summary of results 
The results obtained in the course of this project suggest that ADAM10 is 
associated with tetraspanins in its resting form as well as when it is activated.  
Immunoprecipitations combined with neutravidin Western blots have shown that the 
band pattern characteristic of tetraspanins and their partner proteins can be 
detected in both CD9 and ADAM10 IPs performed in biotinylated platelets.  This is 
true of samples that were treated with DMSO and W7.  In contrast, we were not able 
to detect the same band pattern in ADAM17 IPs.  While W7 and NEM both appear to 
increase GPVI cleavage in HEL cells, siRNA-mediated knockdown of ADAM10 did not 
seem to work efficiently in these cells. 
4.2. W7 and NEM induce GPVI shedding in platelets 
The calmodulin inhibitor W7 and thiol-modifying agent NEM have previously 
been used as activators of ADAM10 and have been shown to induce GPVI cleavage 
(53). We confirmed this result using flow cytometry to analyse GPVI levels in PRP and 
washed platelets after treatment with 150 μM W7, 2mM NEM or a vehicle control.  
Interestingly, we also found that there was less GPVI staining in the control washed 
platelets than the PRP.  This is believed to be due to the presence of CaCl2 in the 
Tyrode’s buffer that the washed platelets were resuspended in as increasing the 
intracellular concentration of calcium activates ADAM10 (76).  Calcium is chelated 
during platelet preparation to prevent activation and it is thought that when calcium 
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was added to the DMSO control the platelets took up the free calcium, increasing the 
intracellular concentration and activating ADAM10.   
 
Treating platelets with W7 or NEM also increased the levels of CD9 staining.  
This is thought to be caused by ADAM10-mediated cleavage of other surface proteins 
in addition to GPVI.  It is possible that as the extracellular domains of various proteins 
were cleaved the CD9 antibodies were more able to access and bind to CD9, 
therefore increasing the level of staining seen when flow cytometry was performed.  
This could be confirmed by determining the other targets of ADAM10 on platelets 
and assessing whether removing these from the platelet surface gave a similar 
increase in CD9 staining.  Identifying ADAM10’s target proteins will indicate the size 
of the extracellular domains being cleaved.  Finding that these domains are relatively 
large will support the theory that CD9 staining is increased after W7 treatment due to 
the antibody being able to access its target. 
 
4.3. ADAM10 is associated with CD9 in human platelets, irrespective of 
activation 
Immunoprecipitations were used to determine whether ADAM10’s 
association with tetraspanins changes upon activation.  Neutravidin Western blots 
showed that ADAM10 was associated with CD9 after treatment with DMSO as well as 
after W7 treatment.  This, combined with the presence of a CD9 band in both the 
CD9 and ADAM10 IPs after CD9 Western blotting, suggests that ADAM10 is 
associated with tetraspanin microdomains irrespective of its activation status.  This 
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result was confirmed by ADAM10 Western blot, which showed a band representing 
ADAM10 in both the ADAM10 and CD9 IPs.  Unlike a previously published study (61), 
we were not able to detect CD9 in the GPVI IP after neutravidin or CD9 Western 
blotting.  This is thought to be because the blots were developed using an infra-red 
imaging system, whereas the data obtained by Protty et al. was from a 
chemiluminescence film blot, which is generally more sensitive than infra-red 
imaging (Tomlinson et al., unpublished data).  It would, therefore, be advisable to 
repeat the experiment with the blot developed on film to confirm that GPVI is 
associated with the tetraspanin microdomain.  
 
It was suggested that the presence of calcium ions in the Tyrode’s buffer that 
the platelets were resuspended in may be affecting the assay.  Therefore, the 
experiment was repeated without CaCl2 in the DMSO control, but it was kept in the 
W7 treatment as calcium ions are necessary for the activation of ADAM10 (77).  The 
neutravidin blots from these repeat experiments still showed that inactive ADAM10 
was associated with tetraspanins.  Therefore, it can be concluded that while calcium 
leads to a reduction in surface levels of GPVI it does not affect ADAM10 localisation 
within the tetraspanin microdomain. 
 
There was also a difference in band intensity between the DMSO-treated and 
W7-treated samples.  Initially, we suspected that this was due to different amounts 
of protein in the samples, but confirmed that this was not the case and that there 
were equal amounts of protein.  Therefore, we believe that the cleavage of 
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extracellular domains by ADAM10 makes the remaining non-target platelet proteins 
more accessible, thus increasing the biotinylation of proteins on W7-treated 
platelets.  
 
4.4. ADAM17 does not appear to be associated with CD9 in human 
platelets 
There is currently some debate as to whether ADAM17 is associated with CD9, 
due to conflicting reports published in the last few years (70-72).  
Immunoprecipitation experiments in biotinylated platelets showed a definite 
association between ADAM10 and CD9, but suggested that ADAM17 is not associated 
with CD9.  The ADAM17 band was relatively difficult to detect, but was visible when 
the exposure on the image was increased.  Only the IPs performed in Brij97 lysis 
buffer showed the ADAM10-CD9 association as the Triton X-100 lysis buffer contains 
a more stringent detergent, which disrupts the tetraspanin microdomain. 
 
Although the data shown here suggests that ADAM17 is not associated with 
CD9, the possibility that ADAM17 is tetraspanin-associated cannot be completely 
discarded.  CD9 is relatively abundant on the platelet surface, with 45,000 copies 
(78), so it was thought that any association with ADAM17 would be reasonably easy 
to detect.  However, there is a large deviation between ADAM10 and ADAM17 levels 
on platelets, with ADAM10 being significantly more abundant as assessed by 
proteomics (59), and yet the CD9 band in the ADAM10 IP was comparatively weak.  
Therefore, it is possible that ADAM17 is associated with CD9 but the low levels of 
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ADAM17 on platelets means the association cannot be detected using this method.  
To check whether this is the case the experiment should be repeated in a different 
cell type, preferably one in which ADAM10 and ADAM17 are expressed at similar 
levels.  This difference in ADAM17 expression may also explain why Gutierrez-Lopez 
(72) reported the association when it had not been detected by other groups (70,71).  
The other possibility is that the ADAM17 antibody failed to bind properly.  To assess 
this, flow cytometry could be performed using washed platelets to check whether the 
ADAM17 antibody is binding before repeating the immunoprecipitation experiments. 
 
4.5. W7 and NEM induce GPVI cleavage in HEL cells 
One of the aims of this project was to assess whether the megakaryocyte-like 
HEL cell line would be an appropriate system in which to study the effects of 
tetraspanins on ADAM10 activity and GPVI cleavage.  The first stage in this 
assessment was to confirm that W7 and NEM were able to activate ADAM10 in these 
cells.  Flow cytometry after incubation with either W7 or NEM showed that GPVI is 
reduced after treatment with these compounds.   
A greater reduction in GPVI was observed with NEM.  The reason for this is 
currently unclear, but it may be that there are other metalloproteinases on the cell 
surface that are able to cleave GPVI.  Matrix metalloproteinases also contain a 
cysteine switch that regulates their activation, so are likely to be activated by NEM 
(79), whereas W7 is thought to be a more specific activator of ADAM 
metalloproteinases, which may result in a lower level of GPVI cleavage compared to 
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NEM.  The GPVI staining intensity was much lower in this experiment than in the 
earlier platelet experiment.  This is probably due to the low cell number that was 
used in the experiment, which resulted from the presence of a population of dead 
cells in the samples.  
4.6. siRNA-mediated knockdown of ADAM10 is not appropriate for HEL cells 
FACS analysis of HEL cells 72 hours after transfection showed only a 50 % 
reduction in ADAM10 expression.  In comparison, A549 cells that were transfected 
with the same siRNA showed a 95 % reduction in ADAM10 after 72 hours.  It was 
suggested that the disappointing knockdown level was due to the time period at 
which the cells were assessed: there may have been residual ADAM10 protein or the 
cells may have begun to re-express ADAM10.  To test this, a time course study was 
performed with analysis of ADAM10 expression at 48, 72 and 96 hours after 
transfection.  However, the ADAM10 knockdown seen in this experiment did not 
improve on the previously obtained data, suggesting that siRNA transfection is not 
appropriate for HEL cells. 
 
It is possible that the problem in this experiment was with the transfection 
reagent rather than the cell line.  The transfection was performed using RNAiMAX, 
which is a lipid-based transfection reagent.  It may be prudent to repeat the 
experiment with a different transfection agent, such as Dharmafect (Thermo 
Scientific), to see if this improves the transfection efficiency.  Alternatively, lentiviral 
transfection of short hairpin RNA (shRNA) could be used to remove various 
tetraspanins, but particularly the 8-Cys tetraspanins, from HEL cells.  If this is 
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successful the cells could then be used to study the effect of the removal of these 
tetraspanins on ADAM10 function.   
 
If the problem was with the cell line, siRNA transfection may be possible in 
different cell lines.  This would allow the interaction between tetraspanins, ADAM10 
and GPVI to be studied, but may be different to the situation in platelets and 
megakaryocytes, which would have to be taken into account when making 
conclusions from any data that is obtained.  In addition to the ADAM10 knockdown 
not being successful, the GPVI levels in HEL cells were found to be quite low, which 
could make studying GPVI cleavage difficult.  In theory, GPVI cleavage could be 
studied in primary megakaryocytes, but these are extremely difficult to genetically 
manipulate.  Alternatively, a different cell line could be used, such as the 
megakaryocyte-like cell lines Dami and MEG-01.  There is some debate as to whether 
these cell lines truly model megakaryocytes.  The Dami cell line has been known to be 
contaminated with the HEL cell line (80) and, like HEL cells, Dami cells can also 
express erythrocyte markers (81), so may not accurately model megakaryocytes.  
Comparatively, the phenotype of MEG-01 cells is closer to that of primary 
megakaryocytes (82), but like all megakaryocytic cell lines is still thought to be 
biologically different to normal megakaryocytes (83).  Both of these cell lines can also 
be treated with PMA to increase ploidy and make them more megakaryocyte-like 
(81). 
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4.7. Conclusions and future directions 
The hypothesis behind this project was that the localisation of ADAM10 and 
GPVI would change when ADAM10 was activated.  The specific aims of the project 
were (i) to determine whether the localisation of ADAM10 changed upon activation; 
(ii) to confirm whether ADAM17 was associated with CD9 and (iii) to assess whether 
HEL cells would be a suitable system in which to study the interaction between 
tetraspanins, ADAM10 and GPVI.  The data described above indicate that ADAM10 is 
associated with tetraspanin microdomains in both its inactive and active forms and 
that HEL cells may not be the best system in which to study tetraspanins and 
ADAM10.  From the data outlined here it is not possible to conclude whether 
ADAM17 and CD9 are associated or not. 
 
While we have shown that ADAM10 does not change its localisation upon 
activation, the experiment should be repeated with the Western blots developed on 
film to determine whether GPVI is also associated with tetraspanin microdomains 
both before and after treatment with W7.  Further experiments could assess what 
happens to the remaining section of GPVI after the extracellular domain has been 
cleaved: does it remain associated with the tetraspanin microdomain? 
 
The immunoprecipitation experiments attempting to show whether ADAM17 
is associated with CD9 need to be repeated in a different cell type.  In platelets, we 
were not able to detect the association between ADAM17 and CD9.  However, there 
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is significantly more ADAM10 than ADAM17 on the platelet surface (59), which 
means that there may not have been enough ADAM17 in the platelet samples to 
allow the association with CD9 to be detected.  Ideally, the cells in which this 
experiment is repeated should have similar levels of ADAM10 and ADAM17, but 
platelets are one of few cell types that have had their membrane proteins quantified. 
 
Similarly, more work needs to be undertaken in order to find a suitable cell 
line in which to study the effect of tetraspanins on ADAM10.  The megakaryocyte-like 
HEL cell line has so far proven difficult to manipulate through siRNA-mediated 
transfection.  These cells may be suitable for lentiviral transfection, but further 
experiments would be required to confirm this.  As previous data has demonstrated 
that ADAM10 expression is dependent on a number of tetraspanins (70); Collier and 
Tomlinson, unpublished data), it is possible that ADAM10 regulation by tetraspanins 
is compensatory.  Therefore, lentiviral shRNA knockdowns could be used to assess 
the effects of a number of tetraspanins on ADAM10 function.  In particular, 
overexpression of Tspan10, Tspan14 or Tspan33 greatly increases levels of mature 
ADAM10 (Collier and Tomlinson, unpublished data).  With this in mind, experiments 
could knock down these three tetraspanins individually or in combination and assess 
the effect on ADAM10 cleavage of GPVI. 
 
As well as showing the association between ADAM10 and tetraspanins 
biochemically, it would be useful to confirm this with imaging techniques.  For 
example, a bioluminescence resonance energy transfer (BRET) assay could be used to 
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study the interaction in real-time.  It would also be interesting to develop a Tspan14 
knockout mouse, which would allow the work on tetraspanin regulation of ADAM10 
and GPVI to be continued in platelets rather than in a megakaryocyte-like cell line.  
Tspan14 is the primary tetraspanin on mouse platelets as well as being associated 
with ADAM10, so the knockout mouse has the potential to have an interesting 
platelet phenotype.   
 
In summary, ADAM10 is associated with tetraspanins when active and 
inactive.  ADAM17 does not appear to be associated with CD9 in platelets, but this 
should be confirmed in a different cell type.  Finally, HEL cells do not appear to be a 
suitable model for studying ADAM10 regulation by tetraspanins. 
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